hoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom roche annual report annual report landmark year roche personalise healthcare annual report highlight progress advance strategic priority share entire roche group successfully launch new test medicine tailor need specific patient popu lation good progress develop promise treatment safe effective roche believe medically differentiate product benefit healthcare stakeholder patient physician regulator payer rochearfront coverengindd rochearourbusinesstopicengindd landmark year roche personalise healthcare annual report highlight progress advance strategic priority share entire roche group successfully launch new test medicine tailor need specific patient popu lation good progress develop promise treatment safe effective roche believe medically differentiate product benefit healthcare stakeholder patient physician regulator payersour business precise diagnosis target therapy potent new drug blood test guide use life changer patient roche global leader sector world big biopharmaceutical company lead supplier vitro diagnostic innovator major disease area cancer virology business sciencedriven exceptional research development capability develop drug diagnostic drugdiagnostic combination address medicine press challengeskey figure roche group index sale mchf free cash flow mchf research development mchf total dividend mchf operating profit mchf number employee income taxis mchf total employee remuneration mchf net income mchf patient clinical trial core earning share chf ecoefficiency rate index index price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebase key figure index figure annual report core result index global reporting initiative gri propose board director indicator report development phase number exclude patient wwwrochecomreportingandindice genentech study initiate prior merger calculation ecoefficiency rate wwwrochecomenvironment key figure highlight february march march roche group index study avastin show woman roche annual general meeting vote launch innovative fully auto sale mchf free cash flow mchf newly diagnose advanced ovar increase shareholder dividend mate clinical chemistry module ian cancer live significantly long cobas disease get bad research development mchf total dividend mchf operating profit mchf number employee april april roche announce positive clinical fda approve cobas hpv test investigational medicine metmab test result investigational medi cervical cancer screening combination tarceva double cine tdm aggressive form detect highrisk genotype time people lung cancer live metastatic breast cancer disease get bad income taxis mchf total employee remuneration mchf net income mchf patient clinical trial august september september marketing approval target roche name healthcare super tarceva receive european approval skin cancer medicine zelboraf sector leader dow jones firstline use genetically distinct core earning share chf ecoefficiency rate cobas braf test companion sustainability index type lung cancer diagnostic year run index index october november december price development nonvoting equity security genussschein chf investigational medicine ocrelizumab fda grant priority review new marketing application submit show significant reduction drug application vismodegib pertuzumab multiple sclerosis disease main advanced form skin cancer positive metastatic breast cancer taine year roche nonvoting equity security swiss market index rebase key figure index figure annual report core result index global reporting initiative gri propose board director indicator report development phase number exclude patient wwwrochecomreportingandindice genentech study initiate prior merger calculation ecoefficiency rate wwwrochecomenvironment rochearkey figuresengindd rochearhighlightsengindd content key figure inside cover highlight inside cover letter shareholder managementbusiness review group result outlook responsible business market environment group strategy research development pharmaceutical unmet medical need access external innovation diagnostic well treatment decision conduct responsible manufacture procurement manufacture green logistic quality compliance procurement marketing distribution access healthcare customer relationship valueadde service patient safety advocacy people great place work employee development talent attraction reward recognition community involvement humanitarian social project art culture science education community environment environmental stewardship health safety biodiversity environmental footprint pharmaceutical environment corporate governance remuneration report corporate governance remuneration report independent assurance reportletter shareholder roche business report letter shareholdersdear shareholder deepen debt crisis europe united states turbulent currency market slow global economic growth profound impact business landscape increase pressure government budget weigh heavily healthcare market resource stretch country focus shortterm saving target budget control number government particularly europe seek ease deficit impose substantial price cut pharmaceutical include innovative patentprotected medicine measure aim control reduce healthcare expenditure amid challenge roche post strong result year group sale advance constant exchange rate exclude tamiflu billion swiss franc earning performance improve significantly fast net income rise billion swiss franc please dow jones sustainability index name super sector leader healthcare rank roche world sustainable healthcare company consecutive year convince sustainable corporate policy practice create longterm value promote innovation support primary mission company prolong people live improve quality life excellence science researchbase company like recent development healthcare policy policy maker shortterm focus cost major cause concern course understand roche lead pharmaceutical diagnostic company industry play effort overcome current financial debt crisis pre pare constructive dialogue aim contribute find fair sus tainable balance health policy industrial policy balance encourage reward type innovation society benefit nearly decade work healthcare industry rarely optimistic medium longterm outlook researchbase innovationdriven company fundamental trend point right direction grow age global population increa ingly affluent emerge market rapid scientific technological advance pave way target costeffective treatment undiminishe need medical progress disease effectively treat forget increase economic significance innovation fact nation region community globe compete investment job country increasingly take target action promote research innovation border impress progress shanghai beijing singapore cities emerge market strive global leader life science particu larly pharmaceutical diagnostic positive attitude openness new scientific discovery technologie definite asset letter shareholder roche business report country recognise researchbased healthcare industry high productivity translate significant economic growth generate skilled job investment export high expenditure research development lead ultimately strong value creation roche activity continue locate headquarters switzerland precisely country competitive advantage switzerland remain good place world investment science maintain strengthen innovationpro mote advantage particularly optimistic company future decade roche maintain strategic focus innovative diagnostic therapeutic world big biotech company biopharmaceutical market ideally equip transform grow knowledge disease biology novel treatment test spend billion swiss franc research development sum put spender regardless industry unlike competitor intend continue invest ing heavily research development particularly area competitive advantage oncology diabete inflammatory autoimmune disease neuroscience time maintain strong focus optimal use resource continue productivity improvement roche remain world lead supplier cancer medicine number vitro diag nostics company combine strength pharmaceutical diagnostic prove expertise molecular biology company uniquely position personalised healthcare reality achievement past year launch zelboraf record time euro pean medicine agencys positive opinion novel treatment skin cancer progress project development pipeline testimony costeffective target medicine diagnostic key role play overcome health care sector current difficulty pricing pressure increase payer shift resource product service offer great incremental benefit patient company focus develop medicine test create real value patient physician equipped compete successfully increasingly challenging healthcare market strength serve today important tomorrow view company strong performance positive outlook difficult economic financial environment notwithstanding board director propose dividend increase share nonvoting equity security swiss franc subject approval annual general meeting march roche consecutive annual dividend increase finally want inform andr hoffmann prof sir john irving bell highly experi ence distinguished roche board member agree stand election term forthcoming annual general meeting standing reelection chairman honoured continued confidence franz humer chairman board roche business report letter shareholdersdear shareholder give significantly harsh market condition face easy year company successful let look roche financial performance meet target despite significant impact strong swiss franc report result exclude sale influenza medicine tamiflu anticipate sharply previous year group sale advance constant exchange rate pharmaceutical sale line market growth diagnostic division post increase sale reinforce position lead supplier vitro diagnostic group profitability continue improve ongoing productivity gain cost saving impressive give price cut impose product major market core earning share key metric underlie performance exclude noncore item global restructuring charge amortisation impairment intangible asset increase constant exchange rate core operating profit grow strongly fast sale rise currencyadjuste basis billion swiss franc division increase core operate profit margin solid earning performance enable continue invest heavily research cause disease advance grow number latestage project product pipeline success rate clinical trial programme extraordinary make opti mistic roche future few major clinical trial new medi cine report positive datum excellent mark compare industry result help position strongly future growth roche owe success employee thank tremendous dedication hard work meet annual objective challenge market environment behalf executive committee additional opportunity thank roche employee valuable contribution importantly landmark year roche personalise healthcare advance molecular diagnostic therapy increasingly target particular patient population roughly half new molecular entity latestage portfolio tailor subset patient identify specific diagnostic test letter shareholder roche business report zelboraf novel personalise therapy metastatic melanoma aggressive form skin cancer major milestone patient doctor roche food drug administration approve zelboraf companion diagnostic test august follow late year recommendation approval european medicine agency time roche simultaneously launch new medicine companion diagnostic close collaboration pharmaceutical diagnostic division crucial bring ing zelboraf market record time year metastatic melanoma extremely difficult treat hour day patient die disease zelboraf inhibits mutate form braf protein occur half melanomas detect roche test target treatment show extend survival patient metastatic melanoma significantly improve quality life expect approval additional market course zelboraf companion diagnostic available patient worldwide file regulatory approval novel biologic pertuzumab treatment breast cancer instance new drug address significant medical need breast cancer common form cancer woman million new case diag nose annually worldwide breast cancer claim live woman year despite major advance therapy pertuzumab effective roughly breast cancer patient tumour carry genetic mutation cause overproduce protein know receptor herposi tive tumour highly aggressive fast grow associate high risk recurrence pertu zumab designed specifically prevent receptor pairing receptor process believe play important role formation growth type cancer add pertuzumab treatment regimen roche medicine herceptin chemotherapy find reduce risk disease progression death impressive clinical trial datum encourage drug combination new standard firstline treatment herpositive breast cancer aspire good treatment option well goal cancer certain death sentence increasingly chronic condition unfortunately cancer eventu ally develop resistance therapy cancer cell master evasion start grow multiplying combination regimen attack cancer front simultaneously gain importance zelboraf pertuzumab tangible example field cancer deliver significant benefit patient excellence science intend build success like oncology therapeutic area develop effective target strategy fight disease addition new cancer therapy work personalise medicine hepatitis asthma drug alleviate cure disorder central nervous system include alzheimer disease schizophrenia depression currently drug development project research lead companion diagnostic roche business report letter shareholdersmolecular biology usher new era medicine clear strategic advantage field figure prominently success go forward understand underlie biology disease grow ability develop target medicine companion diagnostic increasingly make personalised healthcare reality hold tremendous potential patient healthcare system roche encounter significant challenge opportunity year ahead roche respond boldly decisively continue serve interest patient employee shareholder thank continued confidence company severin schwan chief executive officer letter shareholder roche business report board director franz humer prof bruno gehrig andr hoffmann andreas oeri prof pius baschera prof sir john irving bell paul bulcke william burns lodewijk vink christoph franz deanne julius arthur levinson board director december peter voser prof beatrice weder mauro roche business report managementboard director year birth term end elect board director franz humer chairman prof bruno gehrig vicechairman andr hoffmann vicechairman prof pius baschera prof sir john irving bell paul bulcke william burns lodewijk vink christoph franz deanne julius arthur levinson andreas oeri peter voser prof beatrice weder mauro secretary board directors gottlieb keller honorary chairman board directors fritz gerber corporate governance sustainability committee audit committee remuneration committee presidiumnomination committee nonexecutive director committee chairperson management roche business report corporate executive committee severin schwan pascal soriot daniel oday alan hippe silvia ayyoubi gottlieb keller richard scheller jeanjacques garaud dan zabrowski osamu nagayama stephan feldhaus sophie kornowskibonnet member february corporate executive committee december roche business report managementcorporate executive committee year birth position corporate executive committee severin schwan ceo roche group alan hippe chief financial officer pascal soriot coo division roche pharmaceutical daniel oday coo division roche diagnostic gottlieb keller general counsel silvia ayyoubi head group human resource enlarge corporate executive osamu nagayama president ceo chugai committee richard scheller head genentech research early development gre jeanjacques garaud head roche pharma research early development pre stephan feldhaus head group communications february dan zabrowski head roche partnering february sophie kornowskibonnet head roche partnering secretary corporate executive committee perolof attinger statutory auditor kpmg klynveld peat marwick goerdeler reporting year roche holding ltd kpmg auditor charge john morris ian starkey chief compliance officer urs jaisli management roche business report swiss franc core earning share roche business report business review group result roche post strong overall result challenge business environment core operating profit grow fast sale core earning share ep increase doubledigit rate outlook roche expect sale pharmaceutical group grow lowsinglemidsingledigit range diagnostic sale expect grow market roche target high singledigit core eps growth market environment change healthcare sector cost pressure vast potential modern science transform development delivery healthcare innovation centre group strategy strive benefit patient healthcare efficient innovation build excellence science response medical economic challenge face society roche business report business review key figure group sale millions chf cer core operating profit million chf cer net income millions chf cer millions chf change sale cer chf usd group sale excl tamiflu pharmaceutical division excl tamiflu diagnostic division core operate profit pharmaceutical division diagnostic division operate free cash flow core earning share chf cer constant exchange rate average fullyear group result outlook group result group cost base locate outside switzer land roche group post strong overall result challenge market core operating profit grow fast sale solid sale growth core earning share eps increase con group sale increase constant currency stant exchange rate swiss franc strengthen swiss franc dollar billion swiss franc e swiss franc major currency notably underlie growth able compensate expect dollar euro significant negative impact decline tamiflu avastin sale impact health result express swiss franc care reform austerity measure price cut exclude tamiflu sale increase constant currency underlie currency translation exposure arise pharmaceutical division represent group sale nonswiss franc revenue mitigate majority diagnostic division contribute pharmaceutical sale pharmaceutical division exclude tamiflu grow explanation core result concept finance report annual report include tamiflu sale express constant cur roche business report business reviewpharmaceutical division sale region key product certain asiapacific latin american country notably china venezuela brazil western europe united states decrease sale japan exclude tamiflu primarily direct indirect effect disastrous japan earthquake march emergency relief effort rapid implementation chugai recovery programme ensure international product supply restore production take priority marketing activity normal operation resume exclude tamiflu end ensure uninterrupted supply constant exchange rate average fullyear medicine patient shipment control introduce number key product immediately follow earth quake case control maintain rencie remain stable swiss franc fourth quarter promotional activity reduce accord dollar total billion swiss franc sale reflect ingly solid growth key medicine include recently launch product demand cancer medicine herceptin mabthera diagnostic rituxan xeloda tarceva continue grow initial diagnostic sale grow significantly fast vitro sale new target skin cancer medication zelboraf diagnostic ivd market constant exchange rate launch august encourage swiss franc dollar total billion additional major growth driver eye medication swiss franc market share roche continue lucentis actemraroactemra rheumatoid arthritis lead global ivd market business area professional mircera renal anemia negative impact include expect diagnostic tissue diagnostic decrease sale tamiflu avastin metastatic breast main contributor cer indication neorecormonepogin bonvivaboniva cellcept healthcare reform european austerity mea sale professional diagnostic far large business sure base effect japanese biennial price cut area drive continued strong momentum immu combine negative growth impact million swiss noassays solid instrument placement early roche franc equivalent percentage point divisional sale professional diagnostic take leading position market include ivd solution clinical laboratory hos oncology continue account majority pitalambulatory pointofcare testing tissue diagnostic vision sale continue growth herceptin demand advanced stain product detection mabtherarituxan offset expect decline avastin gene protein tissue sample continue fuel growth sale virology sale tamiflu continue decrease sub twice market rate diabete care stantially overall pegasys sale decline year molecular diagnostic new generation accuchek begin recover second half follow launch blood glucose monitoring system viral load test new hepatitis medicine combination infectious disease respectively remain main growth pegasys sale inflammationautoimmunetransplantation driver apply science sale impact increase strong uptake actemraroactemra yearonyear decline influenza virus testing increas growth mabtherarituxan rheumatoid arthritis ing competition sequence slowdown research compensate negative impact continue generic funding erosion cellcept diagnostic sale grow region significant region growth pharmaceutical sale drive contribution establish emerge market mainly demand lucentis rituxan actemra low strong gain record asiapacific drive sale western europe primarily government mainly professional diagnostic immunoassay business austerity measure budget constraint include manda reflect roche diagnostic strong presence china tory price cut high rebate increase utilisation con latin america business area grow trol country exclude tamiflu sale inter great contribution professional diagnostic dia national region grow help increase demand bete care professional diagnostic drive sale business review roche business report diagnostic division sale region sale growth positive effect ongoing pro ductivity improvement europe middle east africa emea net income core eps significantly net income grow strongly mainly good operate japan performance low financing cost low tax rate advance currency adjust basis billion asiapacific swiss franc swiss francs latin america core ep exclude noncore item global restructuring charge amortisation impairment north america intangible asset increase constant currency swiss franc constant exchange rate average fullyear strong operating free cash flow improve net debt position emea europe middle east africa region pricing group operate free cash flow remain strongly posi pressure budget constraint feel north america tive billion swiss franc advance con roche gain market share ivd core business follow stant currency swiss franc launch new immuno assay molecular tissue test decline diabete care sale postpone mainly free cash flow net debt position launch late product portfolio offset group end decrease billion swiss franc strong sale ivd core business sale japan contin billion swiss franc start year bil ued grow time market rate drive gain lion swiss franc net debt asset ratio reach level professional diagnostic tissue diagnostic operating profit improve group core operating profit increase constant outlook currency swiss franc result increase core operating profit margin percentage point roche expect low midsingledigit sale growth con report exchange rate continue pressure stant exchange rate group pharmaceutical sale price compensate increase sale division pharmaceutical sale growth expect volume efficiency measure operating cost decrease accelerate drive strength establish product primarily result operational excellence programme portfolio plan new product launch sale announce november diagnostic division expect outpace market core operate profit pharmaceutical division grow constant exchange rate billion swiss franc despite challenge market environment base core operate profit margin division increase signifi expect sale growth continue efficiency improve cantly percentage point report exchange rate ment roche aim high singledigit increase core drive genentech integration synergy resource prioriti eps constant exchange rate sation productivity improvement achieve spite expect decline tamiflu sale billion roche continue attractive dividend policy swiss franc low sale avastin metastatic breast cancer indication impact healthcare reform austerity measure core operate profit diagnostic division increase constant exchange rate billion swiss franc division core operating profit margin increase percent age point sale report exchange rate drive roche business report business reviewkey achievement businessfinance group sale rise exclude tamiflu significant foreign exchange impact percentage achievement point appreciation swiss franc overall group sale billion swiss franc pharmaceutical sale exclude tamiflu line market diagnostic sale increase significantly ahead market core operating profit increase significantly fast sale drive primarily saving operational excellence programme continue productivity improvement core eps rise solid operating performance low financing cost low tax rate strong operating free cash flow billion swiss franc dividend increase report year board propose dividend increase swiss franc consecutive year dividend growth responsible business roche name healthcare supersector leader dow jones sustainability index consecutive year establish system process report contribution individual healthcare profe sional meet new regulatory requirement research development excellent progress latestage pipeline trial deliver positive result key drug approval major regulatory filing diagnostic test instrument launch key market leading position personalise healthcare strengthen target melanoma medicine zelboraf companion diagnostic test successfully launch tarceva approve egfr mutate nonsmall cell lung cancer launch egfr mutation test marketing application file target cancer medicine vismodegib pertuzumab rich pipeline new molecular entity nme design class good class pharmaceutical diagnostic division collaborate project manufacturing establish unified sustainability audit protocol supplier procurement industry member market distribution basic principle swiss health technology assessment develop joint initiative pharmaceutical industry santsuisse association swiss health insurer continue explore differential pricing model increase access medicine emerge market patient assistance programme china host annual international experience exchange patient organisation share challenge good practice build relationship people run firstever global employee survey roche group participation rate prepare worldwide launch chris global solution host employeerelate information major human resource process increase number woman key position line year goal increase community involvement commence building equip school haiti pakistan follow devastation cause natural disaster lay foundation stone new teacher train college malawi design house train teacher environmental stewardship improve ecobalance impact employee target improve ecobalance level reduce energy consumption track year goal efficiency improve ment level growth rate constant exchange rate average fullyear business review roche business report market environment group strategy operating environment genetic difference patient main rea son good treatment ineffec industrys operating environment characterise tive people different medicine differenti oppose set force experience drive force ate difference identify efficacy form constantly increase demand well healthcare medicine increase significantly diagnostic testing solution industrialise emerge market couple hold tremendous potential improve response rate dramatic progress medical science technology today account healthcare spending help provide tool meet demand con diagnostic add value entire healthcare trast industry face resist force unprecedented chain prevention diagnosis monitoring direct pricing pressure increase regulatory hurdle innova medical decisionmake tion view agent bring decisive positive change environment achieve sustainable demand well healthcare drive growth expand world population expect grow seven billion billion additionally sus grow demand well healthcare option taine economic growth ageing population unhealthy despite continue breakthrough treat disease lifestyle point rise prevalence acute chronic dis need medical care new treatment test ease cancer diabete rheumatoid arthritis respira remain enormous twothird know disease tory disease parkinson alzheimer disease undiagnosed untreated treat main noncommunicable disease cardiovascular disease ment exist response rate unsatisfactory cancer chronic lung disease diabetes kill patient average respond favourably today medicine people worldwide cause great socioeconomic treatment cause effect harm especially develop world patient worldwide wait well treatment option million diagnose cancer year oncology million live asthma million live rheumatoid arthritis inflammation autoimmune disorder million infect hepatitis virology million die cardiovascular disease year million living diabete metabolism million living schizophrenia million live multiple sclerosis neuroscience roche business report business reviewincrease price pressure major market offset high upfront investment generate clinical datum dem growth emerge market onstrate medical value slowdown growth pharmaceutical market low singledigit rate recent year reflect rise number time healthcare authority researchdriven major product go offpatent conse company work closely adapt quence face generic competition addition political pre rapid advance medical science improve regulatory sure contain healthcare cost lead country science science develop tool standard impose significant price reduction pharmaceutical prod proache assess safety value new product uct concert austerity measure take govern ment germany france spain greece pharmaceutical company challenge justify european country governmentmandate price cut value product country imple introduce japan china india brazil russia mente health technology assessment hta procedure government impose fee brand pharma improve healthcare service make pricing reimburse ceutical product ongoing healthcare reform ment funding decision method evidence saving expect come year medi base medicine rapidly evolve field europe care medicaidfunde medicine result country introduce value cost containment measure overall growth develop mar base decisionmake valuebase pricing hta ket expect remain stagnant system meet expectation need citizen consequently decision medicine administer contrast modest outlook industrialise country increasingly public agency health expect continue high growth emerge market insurer physician robust outlook underpin rapid population increase rise personal income effort improve access expand knowledge disease biology basic healthcare expect favourable longterm present vast potential trend lead rise awareness health issue science transform delivery healthcare increase voice patient virtually major emerge today medicine address target market million protein human body implicate disease clearly begin today emerge country health ning understand disease process care market asian market grow twice fast overall global market recent year population vast potential advance steadily billion china world secondlarg economic reveal finding new branch research power large pharmaceutical market nearly genomic proteomic researcher refine knowl quarter chinese population reach age edge disease molecular level insight lead incidence rate cancer chronic dis e new strategy detect fighting disease ease increase population age addition govern example knowledge derive molecular research ment rapidly build diagnostic infrastructure cancer cancer term cover approximately require highly automate instrument bridge gap different condition affect body number skilled laboratory personnel tissue thanks ultramodern method sequence genome scientist know gene involve political volatility talent retention signifi genesis cancer include breast cancer gene challenge emerge market hold signifi brca brca recently discover mutate gene potential industry find malignant melanomas approx imately solid tumour rise regulatory hurdle safety value healthcare authority particularly europe search identify gene critical development continuously raise standard assess ther cancer mean complete scientist worldwide apeutic benefit safety new drug take participate cancer genome project integrate year average bring new pharmaceutical prod research venture aim detect mutation uct market new diagnostic require increasingly cause common type cancer effort hold enormous promise rapidly expand knowl business review roche business report edge disease biology turn transform treatment continue anticipate create new trend disease target diagnostic method medicine harnessing increase understanding disease biology adapt genetic constitution degenerate cell tomorrow treatment safe effective personalised well fit patient genetic characteristic past decade roche pursue roche strategy strategy develop medically differentiate medicine diagnostic believe product likely roche mission remain virtually unchanged obtain regulatory approval accept patient physi company found improve health help cians payer provide value entire patient live long well live entrepreneurial spirit healthcare system turn stakeholder inventiveness founder define culture today provide basis medical advance focus innovation pharmaceutical diagnostic pioneer roche development therapeutic anti convince innovation healthcare drive body lead company world force discover develop well cost leader cancer medicine efficient treatment focus prescription medicine understand disease mechanism new technology allow well understanding disease number plausible target pathway dna structure genetic code human genome cellsorganisms observational disease biology basic biological mechanism mechanism pre today roche business report business reviewworke discovery market diagnostic research assay technically validate ivd assay clinically validate ivd assay biomarker tool pipeline project medicine antibodie sequence lung cancer test disease mechanism asthma hepatitis pharma research development commercialisation vitro diagnostic test ivds create real value diagnostic diagnostic division far world patient physician roche position succeed lead supplier ivds market share increasingly challenge operate environment cost pre develop instrument test disease screen diag sure mount payers channel funding option offer nosis monitor laboratory point care great incremental benefit patient patient selfmanagement division continue success depend focused pursuit testing efficiency strategically align organisation pharma medical value testing efficiency mean offer lab ceutical diagnositic division encourage inter oratory complete test menus solution efficient work divisional collaboration value chain flow information management ensure patient discovery commercialisation create distinct receive fast accurate reliable test result competitive advantage target therapy offer medical devote substantial resource acquire intellectual prop economic value exceed option erty develop novel ivds high medical value provide patient physician answer key medical pharmaceutical diagnostic division question validate demonstrate medical succeed right give distinct business economic benefit test model success factor maintain separate organisation business include product leader leverage expertise molecular biology ship responsibility align group rapidly expand knowledge base disease biology value chain advance personalise healthcare cause disease hold enormous potential pro vide significant benefit patient early understanding pharmaceutical pharmaceutical division strive molecular biology prompt significant investment discover develop bestinclass target thera genetic engineering relate molecular science pie provide unique benefit patient pursue sci exciting new approach infancy today entific excellence maintain high level roche world large biotechnology company expect continue deliver medically differentiate prod biological product market biologic constitute uct address unmet medical need focus product portfolio compare industry aver area believe expertise differ age ence oncology virology inflammatory autoimmune disor ders cardiovascular metabolic disorder disease understand molecular mechanism disease central nervous system grow ability develop target treatment important contribution healthcare management business review roche business report society strength biotechnology research devel talent management process design opment manufacturing mean ideally equip recognise drive innovation focus create transform breakthrough innovation science benefit work environment feel value patient respect foster diversity essential success strive increase number female key posi deliver personalise healthcare tion level comb expertise strength diagnostic pharmaceutical pave way roche personal create sustainable value ise healthcare draw grow body knowledge commitment discover develop innovative research finding molecular cause dis product service commercially medi ease demonstrate case personal cally successful continue important ise healthcare contribution society roche business sustainability identifie patient likely well respond specific creation share value aim provide value treatment stakeholder patient doctor employee inve enhance cost effectiveness healthcare tor society large success improve stratification patient population patient live hinge largely ability integrate ele increase efficiency productivity research ment sustainability social environmental economic development operation culture support development safe effective treat ment reduce risk cost effect strive achieve follow aspect improve medical outcome quality life patient business innovation focus pharmaceutical diag today interweave knowledge pharmaceu nostic tical diagnostic division increase effectiveness broad access product patient need new development process new medicine medicine test respect employee include offer highquality novel active substance excellent rewarding employment show scientific study skin cancer drug zelboraf companion test make sustainability coor approve record time dinate effort corporate sustainability cancer drug tarceva receive approval committee encourage corporate culture seek additional indication link use roche diagnostic high level sustainability roche acknowl test edge united nations guide principle business onehalf medicine latestage development human right recognise follow international companion test tailor specific patient popula standard iso guidance social responsibility tion pharmaceutical project biomarker pro effectiveness approach reaffirm gramme roche name sustainable global health care company consecutive year dow jones foster innovation empower people sustainability index roche rely global network specialised research cen tre operate high degree autonomy addition roche pharmaceutical partner company worldwide approach reflect view innovative research stem fresh idea likely flourish company strong inhouse capability diverse external network partnership goal lead innovation science combin e critical mass big pharma flexibility entrepreneurial spirit small business unit extend roche business report business reviewroche personalised healthcare common cause landmark year roche personalise healthcare feature highlight subject different angle personalise healthcare work today finding new basic research discipline enable scientist refine understanding disease molecular level identify subgroup outwardly similar patient disorder different cause roche making personalise healthcare reality combine strength pharmaceutical diagnostic prove expertise molecular biology roche commit systematic pursuit personalise healthcare concept reality development project intervene molecular level cancer case point important insight derive molecular research thank ultramodern research technique include series innovative system roche today scientist identify gene involve genesis cancer serve behand blu ins est oche target thr enrapy personalise treatment strategy infection hepatitis virus cause liver disease information infect viral subtype help doctor choose right treatment wochen duration predict likelihood last virological response therapie einstellung der behandlung test woche test woche hcvkonzentration virusmenge roche personabliusesidn ehsesa rltehvciaerwe rroocchhee bbuussiinneessss rreeppoorrtt signifikant gesunken geir insm gfe ige gesunken wochene bte hlu dlung virusmenge therapie keine abnahme rochearboxe featuresengindd responsible business corporate culture build value integrity cour clude regional meeting local compliance officer age passion passionate improve patient report implementation roche comprehensive life courage appropriate risk anticorruption programme marketing sale know manage risk competently compliance questionnaire furthermore roche line manager high standard integrity value underpin cor sign assurance declaration confirm compliance porate responsibility employee comply commitment implement control enforc law regulation standard commitment responsi ing roche integrity standard ble behaviour go strict legal compliance demand conduct ethical open create longterm roche require partner supplier party value stakeholder collaborate adhere high standard employee local manager responsible monitoring report compliance roche integrity standard integrity compliance respond quickly noncompliant behaviour roche business partner assist work introduce roche group code conduct guide employee anticorruption compliance questionnaire roche busi business behaviour worldwide clearly express roche ness partner expectation employer code conduct cover ics corporate personal integrity social responsi fair correct behaviour competition mandatory bility compliance management provide information roche employee update behaviour find help advice raise compliance competition compliance questionnaire enable concern sonnel affect competition law selfassess monitor behaviour behaviour help comply roche standard business behaviour employee report additionally update provide employee appropriate instruction guidance roche guideline appropriate behaviour event support include mandatory series interactive elearning investigation authority program roche leader oblige carefully consider business behaviour guideline select new regulatory requirement involve transparency structe monitor people report socalle sunshine act provision similar provision country require company publically chief compliance officer support network report payment contribution grant individual compliance officer group audit risk advisory line healthcare professional institution meet new management commit ensure roche group reporting requirement roche set extensive internal code conduct consistently comply report system monitor contribution patient company officer serve contact shareholder organisation health institution healthcare professional employee customer supplier general public ensure payment comply roche issue relate implementation compliance integrity standard code conduct report compliance roche maintain worldwide network export control employee expect report code conduct viola compliance officer ensure conform foreign trade tion line manager local compliance officer control legislation chief compliance officer alternatively encourage report noncompliance issue anonymously strengthen compliance roche speakup line establish addition comprehensive compliance pro access language country addition gramme launch initiative focus ally material violation roche integrity standard anticorruption good marketing practice report business ethic incident report system roche business report business reviewroche tolerate violations code conduct political donation employee violate code hold accountable sanction appropriate way include termina roche remain independent political affiliation tion employment receive incident report roche speakup line business ethic switzerland roche spend million swiss franc reporting system investigate incident take contribution donation organisation safe corrective measure necessary employment con guard interest include payment interpharma tract terminate account unethical behaviour economiesuisse scienceindustrie swissholding vari ous chambers commerce financial assistance trade union donation political party cantonal risk crisis management federal level donation political party lowdou bledigit thousand franc sum overall total risk management charter set approach iden contribution donation tifye manage report internal external risk use stakeholder feedback help manage social environ employee personal political contri mental ethical risk risk management charter bution roche good government committee available website list principal risk genentech genenpac voluntary bipartisan non business profit political action committee employee donate dollar political campaign com consistent methodology process routinely mittee perform risk assessment level organisation group risk report cover material risk annually discuss corporate executive committee web audit committee board director regularly update risk management process raise awareness roche group code conduct wwwrochecomcodeofconduct group policy position guideline wwwrochecom understand risk roche group policiesguidelinesandposition drug development instance develop risk man risk management compliance wwwrochecom riskmanagementandcompliance agement methodology identify manage risk responsible marketing wwwrochecom impact achievement development project businessintegrityandresponsiblemarkete goal additionally establish incident management team roche group ensure act quickly emergency team regularly rehearse different crisis scenario alert escalation procedure strengthen business continuity management include establish business continuity management task force ensure site respond effectively cata strophic event importance effort high light tsunami strike japan march widespread flooding thailand fall task force develop groupwide business continuity framework guideline local implementation work con tinue goal establish strategy response mitigate business continuity risk business review roche business report collaboration pharmaceutical diagnostic roche business report research development collaboration pharmaceutical commit million swiss franc invest research development diagnostic innovative pharmaceutical pipeline strong industry january include project involve new molecular entity additional indication line extension exist medicine successful pharmaceutical division file major marketing application include new molecular entity gain major approval announce positive result latestage clinical trial impactful diagnostic division launch test deliver enhance information medical decisionmake new upgrade instrument key market integrate pharmaceutical diagnostic division collaborate project therapeutic area interest roche roche business report research development key figure core expenditure roche group millions chf cer sales pharmaceuticals millions chf cer sale diagnostic millions chf cer sale decrease resource prioritisation saving operational excellence programme constant exchange rate average fullyear employee roche group pharmaceutical diagnostic patient clinical trial pharmaceutical clinical development project phase phase phase iii registration new molecular entity investigational new medicine line extension additional indication new dosage form market investigational medicine strategy company world invest quest continue develop new well diagnostic system innovative healthcare solution roche invest expand range test perform billion swiss franc core basis decline broadest vitro diagnostic industry currencyadjuste basis versus patient currently enrol clinical trial people react differently medication variation involve investigational currently market roche group genetic makeup identify specific gene variant medicine plan maintain high level investment determine certain treatment work tolerate continue advanced project key element research development effort market launch ensure steady flow promis drive personalise healthcare approach fit e new compound latestage development treatment define group patient success depends systematically leverage combined capabili tie pharmaceutical diagnostic division year roche show interweave explanation core result concept finance report annual report diagnostic pharmaceutical expertise increasingly pave roche business report research developmentunique structure foster innovation research latestage early development development roche pharma pre genentech gre pharma medicine pme roche partnering chugai pharmaceutical roche diagnostic way personalise healthcare especially oncology pharmaceutical diagnostic division immunology neuroscience aim different process division provide healthcare professional patient pow share research facility technology discovery erful diagnostic tool target treatment base new work internal project unique insight disease arise molecular level advantage set roche apart company diagnostic tool find increase use pharmaceutical diversity approach research importantly close cooperation basis successful implementation personalise healthcare scientific breakthrough likely occur scien strategy roche identify multitude potential biomark tist free tackle problem different angle er evaluate disease process different way roche scientist freedom believe stand disease diversity identify drug target recognise diversity view culture approach promote difference patient biomarker find creativity especially research early development pharma standardise diagnostic test develop dur research early development pre genentech research e clinical trial prepare regulatory approval early development gre roche diagnostic chu drug gai operate independently group form hubs innovation network include alliance today roche biomarker programme dedicate bio outside partner university research institute marker team drug development pharmaceu biotech company roche recognise tical diagnostic division currently collaborate industry partner organisation project therapeutic area interest partner turn multiplicity idea medical roche half project oncology innovation current project roche follow inflammationimmunology neuroscience virology pipeline come alliance find detail metabolic disease group partner activity access external innovation collaborative effort improve prospect effective healthcare well use healthcare resource efficiency bring new therapy collaborate discovery diagnostic test market commercialisation past year continuously improve biomarker characteristic measure evaluated indicator normal biological process disease process organisational technological framework cooperation response treatment research development roche business report number collaboration roche pharmaceutical roche diagnostic improve development pipeline personalise healthcare continue intensify effort improve produc tivity innovate drug development personal ise healthcare approach area roche grow number new drug group expertise molecular biology give clear com candidate diagnostic test petitive advantage roche produce steady flow new drug candidate understand heterogeneity disease diag diagnostic test key therapeutic area past nostic tool improve drug discovery clinical develop year leverage strength biotechnology vitro ment identify well drug target select patient diagnostic end latestage pipeline include subgroup likely benefit treatment investigational new medicine new molecular entity core roche personalise healthcare nme compare seven targeted approach prove effective reduce develop personalise therapy attrition rate drug candidate well profile drug candidate early stage develop goal case produce new medicine ment class good class commitment follow improve clinical trial result well selection science translate positive result late endpoint strong datum stage clinical trial seven form increase efficacy drug candidate clinical study basis regulatory approval filing result sug recruit suitable patient subgroup gest investigational medicine potential offer significant advance area new allow pursue project treatment option need include breast lung skin stop effect lack significant efficacy cancer asthma adult childhood form rheumatoid patient sample despite promise result arthritis patient end pharmaceutical division clinical development portfolio phase iii registration include new molecular entity nme year early additional indication file marketing appli cation few nme roche pharmaceuti cal development pipeline show page report detail available wwwrochecom diagnostic division effort result launch test new upgrade instrument key mar roche business report research developmentroche companion diagnostic market late development disease area disease drug diagnostic test technology application virology cmv valcyte cmv viral load pcr monitor hbv pegasys hbv viral load pcr monitoring antiviral hbv pegasys peginterferon hbsag levels immunoassay monitor alfab mercksp hcv pegasys peginterferon hcv viral load pcr monitor alfab mercksp hcv merictabine hcv viral load pcr monitor hcv danoprevir hcv viral load pcr monitor hiv antiviral hiv viral load pcr monitor hiv abacavir glaxosmithkline hlab genotype pcr screen oncology breast cancer herceptin lapatinib expression ihc ish selection glaxosmithkline gene amplification breast cancer tamoxifen erpr expression ihc selection hormonal therapie breast cancer pertuzumab expression ihc ish selection gene amplification breast cancer trastuzumab emtansine expression ihc ish selection tdm gene amplification cancer compound merck mutations microarray selection colon cancer cetuximab merck kras mutation pcr selection colon cancer panitumumab amgen kra mutation pcr selection gastric cancer herceptin expression ihc ish selection gene amplification melanoma zelboraf braf mutation pcr selection nsclc tarceva egfr mutations pcr selection gefitinib astrazeneca nsclc onartuzumab meet expression ihc selection metmab nsclc transgene muc expression ihc selection nsclc crizotinib pfizer alk ihc selection pancreatic cancer clovi oncology hent expression ihc selection sarcoma mdm antagonist mutation pcr selection inflammation asthma lebrikizumab serum periostin immunoassay selection level rheumatoid mabtherarituxan anticcp immunoassay selection arthritis osteoporosis bonvivaboniva bcrosslap immunoassay monitoring bisphosphonate pnp level transplantation cellcept mpa level immunoassay monitoring project pharmaceutical company disclose confidentiality reason available market selection patient eligible firstline treatment black type market grey type development monitor monitor patient response particular treatment screening screen patient particular genetic variation hla associate hypersensitivity abacavir selection selection patient eligible particular treatment alk anaplastic lymphoma receptor tyrosine kinase anticcp antibodie cyclic citrullinate peptide braf bisoform rapidly grow fibrosarcoma oncogene cmv cytomegalovirus egfr epidermal growth factor receptor erpr estrogen receptorprogesterone receptor hbv hepatitis virus hbsag hbv surface antigen hcv hepatitis virus human epidermal growth factor receptor hiv human immuno deficiency virus hent human equilibrative nucleoside transporter hla human leucocyte antigen ihc immunohistochemistry ish situ hybridisation kras member ras family oncogene mpa mycophenolic acid nsclc nonsmall cell lung cancer pcr polymerase chain reaction pnp procollagen type nterminal propeptide rheumatoid factor schering plough research development roche business report ket product launch enhance information avail result clinical study brim brim able guide treatment decision drive efficiency clini demonstrate significant clinical benefit zelboraf cal laboratorie research centre patient braf vmutate unresectable metastatic melanoma file marketing application number country worldwide include australia new zea pharmaceutical unmet land rate malignant melanoma high roche medical need diagnostic braf test receive mark certification august addition progress key investigational compound roche pass significant regulatory develop zelboraf vemurafenib plx codevel ment milestone currently market medicine ope licence collaboration agreement overview find table clinical trial approv roche plexxikon member daiichi sankyo al filing page main regulatory group zelboraf design target inhibit mutate clinical highlight programme field oncology form braf protein find half case immunology ophthalmology summarise melanoma deadly aggressive form skin gether status update promise investigational medi cer braf protein key component rasraf cine develop address viral disease disorder pathway involve normal cell growth survival certain central nervous system mutation position braf protein active state cause excessive signal pathway lead ing uncontrolle cell growth survival roche con oncology ducting broad development programme zelboraf include test combination medicine currently new compound development approve investigational roche genentech oncology addition obtain positive result key company study tumour type clinical trial file marketing application december collaboration bristol myers squibb advance investigational new medicine initiate phase iii study combine zelboraf yervoy european union zelboraf metastatic melanoma ipilimumab brafmutate metastatic melanoma approve switzerland brazil vismodegib basal cell carcinoma form skin cancer pertuzu vismodegib file bcc skin cancer mab herpositive metastatic breast cancer addition november fda accept file genentech new significant progress development drug application vismodegib treatment adult investigational compound project aim extend advanced basal cell carcinoma bcc surgery ing approve indication introduce new dosage form consider inappropriate application grant pri market product avastin herceptin tarceva ority review status fda assign action date march december roche submit marketing zelboraf approve metastatic melanoma application indication application august food drug administration fda base result pivotal phase erivance bcc approve zelboraf treatment braf mutation study show vismodegib substantially shrank positive inoperable metastatic melanoma determine tumour heal visible lesion patient locally fdaapprove test fda simultaneously approve advanced bcc patient metastatic bcc vis roche diagnostic cobas braf test companion diagnostic modegib investigational oral target medi identify patient treatment zelboraf cine design selectively inhibit abnormal signal appropriate approval enable genentech launch hedgehog pathway underlie molecular driver bcc new oral target cancer medicine implicate case roche develop month marketing application file ing vismodegib collaboration agreement curis year start clinical trial marketing approval bcc common type skin cancer generally obtain switzerland brazil fourth quarter consider curable surgery advanced december european medicine agencys committee medicinal product human use chmp unanimously recommend zelboraf grant marketing certification vitro diagnostic product complie approval approval recommendation base requirement use roche business report research developmentr project therapeutic area roche genentech research early development late development discovery programme phase project phase iii registration project project ophthalmology ophthalmology virology metabolic metabolism neuroscience neuroscience inflammationimmunology inflammationimmunology oncology oncology bcc cause disfigure debilitate effect hensive blockade signal pathway pertuzumab patient ultimately lifethreatene study current standard care herceptin plus chemotherapy herpositive breast stomach cancer pertuzumab file herpositive breast cancer december submit marketing application avastin regulatory update pertuzumab treatment previously untreated breast cancer july european commission approve herpositive metastatic breast cancer filing base extension avastin breast cancer label avastin result cleopatra randomise phase iii combination xeloda capecitabine study pertuzumab compare combine pertuzu firstline treatment woman metastatic breast cancer mab herceptin trastuzumab docetaxel chemotherapy chemotherapy option consider appro herceptin chemotherapy people previ priate september japanese authority approve avas ously untreate herpositive metastatic breast cancer peo tin treatment inoperable recurrent breast cancer ple receive pertuzumab combination herceptin november fda issue final decision revoke chemotherapy experience reduction risk approval avastin treatment metastatic breast disease worsen death progressionfree survival cer follow recommendation july fda pfs median pfs improve month month expert panel agencys initial notice revocation decem herceptin chemotherapy month pertuzu ber appeal roche removal mab herceptin chemotherapy indication fda decision affect medicine approve indication pertuzumab new class target anticancer agent know dimerisation inhibitor ovarian cancer avastin receive approval december design block dimerisation pair treatment woman newly diagnose advanced member family receptor dimerisa ovarian cancer base result phase iii icon tion believe play important role growth gog trial new approval allow use avastin formation different cancer type mechanism combination standard chemotherapy carboplatin action pertuzumab herceptin believe comple paclitaxel frontline treatment firstline treatment fol ment bind receptor lowing surgery advanced epithelial ovarian primary perito different region think provide compre neal fallopian tube carcinoma roche file additional research development roche business report pharmaceutical division major clinical trial product indication trial phase outcome aim actemra moderate severe rheumatoid actray iiib efficacy remission additional datum arthritis actemra monotherapy safety combine actemra methotrexate actemra rheumatoid arthritis doubleblind run noninferiority efficacy registration subcutaneous domise parallel subcutaneous formulation new dosage form formulation group study iii versus intravenous formulation actemra ankylose spondylitis builder iii builder meet proto registration colspecifie primary endpoint potential new indication programme terminate avastin recurrent platinumsensitive ovarian ocean iii significantly improve pfs registration cancer versus chemotherapy potential new indication avastin previously untreate advanced avaperl iii significantly improve pfs additional datum nonsquamous nsclc maintenance treatment combination pemetrexed chemotherapy avastin herpositive metastatic breast averel iii study meet protocol registration herceptin cancer specify primary endpoint potential new indication dalcetrapib patient chd chd risk dalplaque iib datum suggest possible exploratory equivalent beneficial vascular effect safety efficacy generally tolerate dalcetrapib patient chd chd risk dalvessel iib endothelial function preserve exploratory equivalent change blood pressure safety efficacy generally tolerate herceptin herpositive early breast cancer hannah iii comparable efficacy registration subcutaneous subcutaneous formulation new dosage form formulation versus intravenous formulation personalise medicine lebrikizumab adult asthma adequately control milly significantly improve proof concept lead inhaled corticosteroid prebronchodilator fev personalise medicine lucentis diabetic macular edema compare ride rise iii rapid sustained improve registration sham injection year datum ment vision significantly potential new indication improve eye chart score versus baseline lucentis wet agerelate macular degenera harbor iii efficacy datum support registration tion compare alternative dose initiation highdose new dose regimen regimen monthly lucentis study prn dosing discuss fda obinituzumab relapse indolent nhl headto gauss high response rate proof concept head comparison mabthera versus mabthera phase rituxan iii testing initiate ocrelizumab relapsingremitte multiple sclerosis randomise multi significant reduction disease dosefinde centre placebo activity maintain openlabel extension control study week onartuzumab line nsclc combination oamg final significantly improve pfs proof concept metmab tarceva datum include personalise medicine pertuzumab herpositive metastatic breast cleopatra iii significantly improve progre registration cancer combination herceptin sionfree survival personalise medicine docetaxel tarceva metastatic nonsmall cell lung cancer eurtac iii significantly improve pfs potential new indication epidermal growth factor recep personalise medicine toractivating mutation firstline treatment versus chemotherapy trastuzumab herpositive metastatic breast tdmg significantly improve pfs proof concept emtansine cancer previously untreated personalise medicine tdm positive versus herceptin plus chemotherapy vismodegib advance basal cell carcinoma erivance bcc objective response rate tumour registration singlearm trial shhg shrinkage lesion healing zelboraf previously untreate braf brim iii significantly improve registration mutationpositive metastatic pfs personalise medicine melanoma versus chemotherapy braf bisoform rapidly grow fibrosarcoma oncogene chd coronary heart disease fev force expiratory volume volume air force second take deep breath measure lung function human epidermal growth factor receptor nhl nonhodgkin lymphoma nsclc nonsmall cell lung cancer overall survival time start treatment death pfs progression free survival time start treatment disease progression prn pro nata need roche business report research developmentmarkete application august seek approval avastin herceptin treat million patient use relapse ovarian cancer filing base herpositive breast stomach cancer worldwide result phase iii ocean study result approve country present annual meeting american society clinical oncology asco june avastin tarceva approve genetically distinct type nsclc base regiman halve risk disease get bad august authority approve tarceva use woman recurrent ovarian cancer datum add patient locally advanced metastatic nonsmall cell lung grow body evidence support potential role cancer nsclc egfractivate mutation base avastin disease include icon result phase iii eurtac study additional datum gog trial avastin newly diagnose ovarian cancer approval enable use tarceva firstline mono roche plan decision seek mar therapy people genetically distinct type nsclc keting approval avastin ovarian cancer final overall treatment tarceva setting show survival result phase iii trial available expect triple number patient tumour shrink ovarian cancer sixth type cancer response rate nearly double progressionfree survival avastin approve time patient live disease progress com pare chemotherapy roche file marketing application initial approval metastatic colo indication swiss health authority august rectal cancer avastin bevacizumab anti regulatory submission plan angiogenic therapy widely available treatment patient advance cancer today avastin continue tarceva erlotinib oncedaily oral nonchemotherapy transform cancer care prove survival benefit treatment advanced metastatic nsclc advanced type cancer approve pancreatic cancer shown potently inhibit europe treatment advanced stage colorectal epidermal growth factor receptor egfr protein involve nonsmall cell lung kidney cancer available growth development cancer tarceva develop country treatment patient partnership osi pharmaceutical member glioblastoma type brain tumour avastin approve astellas global group company country include japan breast cancer onartuzumab extend overall survival metpositive nsclc herceptin achieve positive phase iii result final datum key phase trial present asco october roche announce phase iii study hannah annual meeting june show people metastatic achieve primary objective demonstrate compara nsclc tumour high level meet determined ble efficacy new investigational subcutaneous roche tissuebase companion diagnostic live twice mulation herceptin current intravenous infusion long disease get bad live time formulation woman herpositive early breast cancer long overall receive onartuzumab plus tarceva herceptin use halozyme therapeutic enhanze technol compare tarceva phase iii trial combine ogy enable injection large volume medica onartuzumab tarceva second thirdline treatment tion skin formulation take min patient metastatic metpositive nsclc metlung ute administer compare minute start january infusion subcutaneous administration allow patient spend time hospital receive treatment onartuzumab metmab unique monovalent case intravenous delivery onearme monoclonal antibody design target meet protein associate poor outcome cancer herceptin trastuzumab humanise antibody design compound block meet signal cancer cell bind target block function protein produce specifically cellsurface meet receptor onartuzumab specific gene cancercause potential herceptin acti investigate potential treatment metastic vate bodys immune system suppresse nsclc breast colorectal cancer target destroy tumour herceptin demonstrate unprecedented efficacy treat early advanced metastatic herpositive breast cancer positive advanced metastatic stomach cancer research development roche business report pharmaceutical pipeline roche business report research development noitacidni tcudorptcejorp tcejorp sruomut cigolotameh dna dilos tsinogatna mdm sruomut dilos bam rehitna sruomut dilos bam rfsc sruomut dilos rotibihni kemfic amonalem citatsatem bamumilipi faroblez recnac bam kaewt amonalem detatumfarb rotibihni farb sruomut dilos rotibihni laud kem far sruomut dilos bam fglpitna sruomut dilos bam dcitna sruomut dilos rotibihni kem sruomut dilos rotibihni kem recnac mdm sruomut dilos rotibihni tka recnac bam rfgfitna recnac yparehtonummi ruomut recnac etatsorp etagujnoc gurdydobitna recnac nairavo etagujnoc gurdydobitna amohpmyl dna sruomut dilos tsinogatna pai seicnangilam cigolotameh etagujnoc gurdydobitna ditna sruomut dilo cinegoignaitna sruomut cigolotameh etagujnoc gurdydobitna sruomut lailehtipe citatsatem bam rfgerehitna amoleym elpitlum etagujnoc gurdydobitna recnac etagujnoc gurdydobitna recnac etagujnoc gurdydobitna aimekuel citycophpmyl cinorhc rotibihni lcb amohpmyl sruomut rotibihni khc amohpmyl snikgdohnon sruomut dilos desolcsid ton recnac rotibihni kip recnac revil bam nacipylgitna recnac gnul llec llamsnon rotibihni kla uhc sruomut dilos rotibihni esanik uhc recnac eniccav recnac editpep uhc enildn recnac tsaerb citatsatem evitisopreh bamuzutrep recnac cirtsag citatsatem evitisopreh bamuzutrep recnac tsaerb ylrae evitisopreh mdt amonicrac llec lasab elbarepo bigedomsiv recnac tsaerb citatsatem bamtem bamuzutrano enilt recnac latceroloc citatsatem bamtem bamuzutrano sruomut dilos bam rfgeitna recnac dioryht yrallipap faroblez sruomut dilos rotibihni esanik sruomut cigolotameh dna dilos rotibihni rotmk enilt recnac latceroloc citatsatem bam lfgeitna mrof egasod amohpmyl snikgdohnon naxutirarehtbam tnemtaert tnavujda recnac tsaerb evitisopreh nitsava tnemtaert tnavujda recnac tsaerb evitagenreh nitsava tnemtaert tnavujda recnac tsaerb evitagenelpirt nitsava enildn recnac tsaerb citatsatem nitsava tnemtaert tnavujda recnac gnul llec llamsnon nitsava dionicrac ksirhgih nitsava enilt amotsalboilg nitsava senil elpitlum hguorht tnemtaert crc citatsatem nitsava enilt recnac nairavo nitsava mrof egasod recnac tsaerb evitisopreh nitpecreh sraey tnemtaert tnavujda evitisopreh nitpecreh recnac tsaerb ylrae evitisopreh bamuzutrep enilt snoitatum gnitavitcarfge clcsn avecrat tnemtaert tnavujda clcsn avecrat recnac tsaerb citatsatem decnavda evitisopreh etagujnoc gurdydobitna mdt enildr recnac tsaerb citatsatem evitisopreh etagujnoc gurdydobitna mdt enilt recnac tsaerb citatsatem evitisopreh etagujnoc gurdydobitna mdt recnac gnul llec llamsnon citatsatem bamtem bamuzutrano aimekuel citycohpmyl cinorhc bamuzutinibo despaler amohpmyl snikgdohnon tnelodni bamuzutinibo amohpmyl llec egral esuffid bamuzutinibo eniltnorf amohpmyl snikgdohnon tnelodni bamuzutinibo noisufni tsaf amohpmyl snikgdohnon naxutirarehtbam recnac nairavo despal nitsava enilt recnac tsaerb citatsatem evitisopreh bamuzutrep amonicrac llec lasab decnavda bigedomsiv amonalem citatsatem faroblez sesaesid enummiotua bam liitna amhtsa tsinogatna htrc amhtsa bam rplstitna sesaesid enummiotua bam liitna sitirhtra diotamuehr bam liitna uhc amhtsa ereve bamuzikirbel sitiloc evitareclu ateb bam uhr susotamehtyre supul cimetsys bamuzilatnor sitirhtra diotamuehr bam ahpla tlitna amhtsa bam emirp mitna sitilucsav detaicossaacna naxutirarehtbam mrof egasod sitirhtra diotamuehr armetcaorarmetca sitirhtra diotamuehr ylrae armetcaorarmetca bamumilada ridramd sitirhtra diotamuehr armetcaorarmetca airacitru cihtapoidi cinorhc rialox yhtaposehtne lynevus uhc sititapeh tsinoga hrlt esaesid suoitcefni desolcsid ton sititapeh enibaticirem sititapeh riverponad sititapeh rivuborte esaesid yendik cinorhc ksir ralucsavoidrac tsinogatna tac aimedipilsyd recudni acba sesaesid cilobatem desolcsid ton setebaid epyt tsinoga laud plgpig sesaesid cilobatem rotibihni dsh ateb esaesid ralucsavoidracemordny yranoroc etuca bam nitceles pitna stneve ralucsavoidrac noitneverp yradnoce bam ldlxoitna setebaid epyt noitcuder ksir ralucsavoidrac razatilgela noitcuder ksir ralucsavoidrac sisorelcsorehta biparteclad setebaid epyt tlgs nizoflilgofot uhc ekort cimehcsi etuca wodniw emit dednetxe esavitca sredrosid evitingoc tsinoga esrevni aabag msitua tsinogatna rotpecer esaesid sremiehzla rotibihni ecab esaesid sremiehzla bamurenetnag esaesid sremiehzla rotibihni boam noisserpe tsinogatna rulgm noisserpe tnatsisertnemtaert tsinogatna rulgm esaesid sremiehzla bam atebaitna sisorelcs elpitlum gnittimergnispaler bamuzilerco sisorelcs elpitlum evissergorpyramirp bamuzilerco smotpmys evitagen ainerhpozihcs rotibihni ekatpuer enicylg nitrepotib dellortnoc yllamitpobus ainerhpozihcs rotibihni ekatpuer enicylg nitrepotib mrof egasod yrevileddeniatsus emdovrdma sitnecul yhporta cihpargoeg bam rotcafitna dedeen atan orp dma sitnecul amede ralucam citebaid sitnecul aimena decudniyparehtomehc hcope uhc approve rgno roche andor genentechmanaged submit chu chugaimanage approve chmp mabthera brand rituxan positive opinion japan submit actemra brand roactemra personalise healthcare project amd agerelate macular degeneration mab monoclonal antibody breast cancer nsclc nonsmall cell lung cancer crc colorectal cancer rhu recombinant humanise dmardir diseasemodifye antirheumatic subcutaneous drug inadequate response dme diabetic macular edema rvo retinal vein occlusion ygolocno noitammalfni ygolonummi ygoloriv cilobatem ralucsavoidrac snc ygolomlahthpo srehto noitartsiger iii esahp esahp esahp roche business report pharmaceutical pipeline pharmaceutical pipeline roche business report seitenzahlpharmapipelineengindd ddnigneenilepipdrraehcorpharmaceutical pipeline research development roche business report noitacidni tcudorptcejorp tcejorp sruomut cigolotameh dna dilos tsinogatna mdm sruomut dilos bam rehitna sruomut dilos bam rfsc sruomut dilos rotibihni kemfic amonalem citatsatem bamumilipi faroblez recnac bam kaewt amonalem detatumfarb rotibihni farb sruomut dilos rotibihni laud kem far sruomut dilos bam fglpitna sruomut dilos bam dcitna sruomut dilos rotibihni kem sruomut dilos rotibihni kem recnac mdm sruomut dilos rotibihni tka recnac bam rfgfitna recnac yparehtonummi ruomut recnac etatsorp etagujnoc gurdydobitna recnac nairavo etagujnoc gurdydobitna amohpmyl dna sruomut dilos tsinogatna pai seicnangilam cigolotameh etagujnoc gurdydobitna ditna sruomut dilo cinegoignaitna sruomut cigolotameh etagujnoc gurdydobitna sruomut lailehtipe citatsatem bam rfgerehitna amoleym elpitlum etagujnoc gurdydobitna recnac etagujnoc gurdydobitna recnac etagujnoc gurdydobitna aimekuel citycophpmyl cinorhc rotibihni lcb amohpmyl sruomut rotibihni khc amohpmyl snikgdohnon sruomut dilos desolcsid ton recnac rotibihni kip recnac revil bam nacipylgitna recnac gnul llec llamsnon rotibihni kla uhc sruomut dilos rotibihni esanik uhc recnac eniccav recnac editpep uhc enildn recnac tsaerb citatsatem evitisopreh bamuzutrep recnac cirtsag citatsatem evitisopreh bamuzutrep recnac tsaerb ylrae evitisopreh mdt amonicrac llec lasab elbarepo bigedomsiv recnac tsaerb citatsatem bamtem bamuzutrano enilt recnac latceroloc citatsatem bamtem bamuzutrano sruomut dilos bam rfgeitna recnac dioryht yrallipap faroblez sruomut dilos rotibihni esanik sruomut cigolotameh dna dilos rotibihni rotmk enilt recnac latceroloc citatsatem bam lfgeitna mrof egasod amohpmyl snikgdohnon naxutirarehtbam tnemtaert tnavujda recnac tsaerb evitisopreh nitsava tnemtaert tnavujda recnac tsaerb evitagenreh nitsava tnemtaert tnavujda recnac tsaerb evitagenelpirt nitsava enildn recnac tsaerb citatsatem nitsava tnemtaert tnavujda recnac gnul llec llamsnon nitsava dionicrac ksirhgih nitsava enilt amotsalboilg nitsava senil elpitlum hguorht tnemtaert crc citatsatem nitsava enilt recnac nairavo nitsava mrof egasod recnac tsaerb evitisopreh nitpecreh sraey tnemtaert tnavujda evitisopreh nitpecreh recnac tsaerb ylrae evitisopreh bamuzutrep enilt snoitatum gnitavitcarfge clcsn avecrat tnemtaert tnavujda clcsn avecrat recnac tsaerb citatsatem decnavda evitisopreh etagujnoc gurdydobitna mdt enildr recnac tsaerb citatsatem evitisopreh etagujnoc gurdydobitna mdt enilt recnac tsaerb citatsatem evitisopreh etagujnoc gurdydobitna mdt recnac gnul llec llamsnon citatsatem bamtem bamuzutrano aimekuel citycohpmyl cinorhc bamuzutinibo despaler amohpmyl snikgdohnon tnelodni bamuzutinibo amohpmyl llec egral esuffid bamuzutinibo eniltnorf amohpmyl snikgdohnon tnelodni bamuzutinibo noisufni tsaf amohpmyl snikgdohnon naxutirarehtbam recnac nairavo despal nitsava enilt recnac tsaerb citatsatem evitisopreh bamuzutrep amonicrac llec lasab decnavda bigedomsiv amonalem citatsatem faroblez sesaesid enummiotua bam liitna amhtsa tsinogatna htrc amhtsa bam rplstitna sesaesid enummiotua bam liitna sitirhtra diotamuehr bam liitna uhc amhtsa ereve bamuzikirbel sitiloc evitareclu ateb bam uhr susotamehtyre supul cimetsys bamuzilatnor sitirhtra diotamuehr bam ahpla tlitna amhtsa bam emirp mitna sitilucsav detaicossaacna naxutirarehtbam mrof egasod sitirhtra diotamuehr armetcaorarmetca sitirhtra diotamuehr ylrae armetcaorarmetca bamumilada ridramd sitirhtra diotamuehr armetcaorarmetca airacitru cihtapoidi cinorhc rialox yhtaposehtne lynevus uhc sititapeh tsinoga hrlt esaesid suoitcefni desolcsid ton sititapeh enibaticirem sititapeh riverponad sititapeh rivuborte esaesid yendik cinorhc ksir ralucsavoidrac tsinogatna tac aimedipilsyd recudni acba sesaesid cilobatem desolcsid ton setebaid epyt tsinoga laud plgpig sesaesid cilobatem rotibihni dsh ateb esaesid ralucsavoidracemordny yranoroc etuca bam nitceles pitna stneve ralucsavoidrac noitneverp yradnoce bam ldlxoitna setebaid epyt noitcuder ksir ralucsavoidrac razatilgela noitcuder ksir ralucsavoidrac sisorelcsorehta biparteclad setebaid epyt tlgs nizoflilgofot uhc ekort cimehcsi etuca wodniw emit dednetxe esavitca sredrosid evitingoc tsinoga esrevni aabag msitua tsinogatna rotpecer esaesid sremiehzla rotibihni ecab esaesid sremiehzla bamurenetnag esaesid sremiehzla rotibihni boam noisserpe tsinogatna rulgm noisserpe tnatsisertnemtaert tsinogatna rulgm esaesid sremiehzla bam atebaitna sisorelcs elpitlum gnittimergnispaler bamuzilerco sisorelcs elpitlum evissergorpyramirp bamuzilerco smotpmys evitagen ainerhpozihcs rotibihni ekatpuer enicylg nitrepotib dellortnoc yllamitpobus ainerhpozihcs rotibihni ekatpuer enicylg nitrepotib mrof egasod yrevileddeniatsus emdovrdma sitnecul yhporta cihpargoeg bam rotcafitna dedeen atan orp dma sitnecul amede ralucam citebaid sitnecul aimena decudniyparehtomehc hcope uhc approve rgno roche andor genentechmanaged submit chu chugaimanage approve chmp mabthera brand rituxan positive opinion japan submit actemra brand roactemra personalise healthcare project amd agerelate macular degeneration mab monoclonal antibody breast cancer nsclc nonsmall cell lung cancer crc colorectal cancer rhu recombinant humanise dmardir diseasemodifye antirheumatic subcutaneous drug inadequate response dme diabetic macular edema rvo retinal vein occlusion ygolocno noitammalfni ygolonummi ygoloriv cilobatem ralucsavoidrac snc ygolomlahthpo srehto noitartsiger iii esahp esahp esahp roche business report pharmaceutical pipeline pharmaceutical pipeline roche business report seitenzahlpharmapipelineengindd ddnigneenilepipdrraehcortrastuzumab emtansine tdm extend pfs activate immune cell attack cancer cell herpositive breast cancer induce direct cell death september promising phase proofofconcept datum present annual meeting european society medical oncology esmo result tdmg immunology ophthalmology study show patient previously untreate positive metastatic breast cancer receive tdm live regulatory approval filing new datum significantly long disease control progre phase iii clinical trial confirm benefit sionfree survival pfs experience few effect actemraroactemra rheumatoid arthritis typical chemotherapy patient receive standard lucentis people common type eye disease addi treatment herceptin trastuzumab plus docetaxel che tion currently investigational new medicine motherapy recruitment complete phase iii development chronic progressive inflammatory trial emilia compare tdm treatment versus combine autoimmune disorder rheumatoid arthritis ulcerative xeloda lapatinib patient herpositive meta colitis systemic lupus erythematosus asthma static breast cancer progress previous therapy result expect second quarter plan lebrikizumab improve lung function adult asthma use datum basis marketing application europe positive result announce august milly phase second half proofofconcept study investigational medicine leb rikizumab show treatment lebrikizumab result trastuzumab emtansine tdm novel anti significant increase fev measure lung function bodydrug conjugate combine therapeutic effect adult asthma symptom inadequately con trastuzumab active substance herceptin intracel troll inhaled corticosteroid lular delivery highly potent chemotherapy agent specifically target herpositive tumour trastuzumab lebrikizumab humanise monoclonal antibody antibody component block signal herposi develop treatment moderate severe persistent tive cancer cell aggressive send message asthma design bind specifically interleukin patient immune system destroy cancer cell think play key role airway inflam deliver chemotherapy agent directly tumour cell mation hyperresponsiveness obstruction experience induce cell death asthma patient addition contribute feature asthma increase level periostin protein obinituzumab increase overall response rate measure blood test milly patient high relapse nhl pretreatment periostin level experience great improve final result phase study gauss compare single ment lung function lebrikizumab patient low agent obinituzumab singleagent mabtherarituxan periostin level result support investigation rituximab patient relapse indolent nonhodgkin lebrikizumab potential personalise medicine patient lymphoma nhl announce half suffer moderate severe uncontrolled asthma present annual meeting american society roche develop periostin immunoassay companion hematology december study show obinituzu diagnostic test support phase iii study mab increase overall response rate orr patient lebrikizumab plan start early indolent nhl common type blood cancer compare mabtherarituxan phase iii registration actemraroactemra approve childhood arthritis trial firstline diffuse large bcell lymphoma dlbcl april fda approve actemra treatment active firstline indolent nhl initiate phase iii pro systemic juvenile idiopathic arthritis sjia know juve gramme include ongoing study assess nile rheumatoid arthritis rare debilitate form arthritis obinituzumab chronic lymphocytic leukemia cll child age year old european commission relapsedrefractory indolent nhl approve roactemra indication august approv als base positive datum phase iii tender study obinituzumab type glycoengineere show treatment actemraroactemra anticd monoclonal antibody develop significantly improve sign symptom sjia actemra tential treatment nhl cll specifically roactemra give combination meth design enhance destruction cancerous cell otrexate patient sjia roche business report research developmenteffective twoyear phase macular edema follow retinal vein occlusion rvo lllb study actray show actemraroactemra lucentis design bind inhibit vegf protein effective people believe play critical role formation new blood respond methotrexate mtx result demonstrate vessel angiogenesis hyperpermeability leakiness actemraroactemra comparable clinical effi vessel wet amd blood vessel grow cacy actemraroactemra plus mtx diseasemodifye retina leak blood fluid cause rapid damage antirheumatic drug widely prescribe people macula central portion retina rvo angiogenesis people give mtx adequately respond hyperpermeability lead macular edema swell treatment experience adverse event require thickening macula macular degeneration mac drug help control inflammation ular edema lead impairment loss vision lucentis discover genentech retain commercial right noninferiority new subcutaneous formulation july novartis exclusive commercial right rest chugai announce positive result phase iii trial world new subcutaneous formulation actemra patient show noninferiority efficacy new formulation compare current intravenous formulation subcuta virology neous injection convenient patient healthcare provider require intravenous access take expand portfolio investigational time administer intravenous infusion sub medicine hepatitis cutaneous formulation develop chugai japan hepatitis market evolve meet different jointly chugai roche outside japan filing need people infect hepatitis virus hcv plan future treatment option likely include interferonfree interferoncontaine triple quadruplecombina actemra tocilizumab know roactemra europe tion therapy regimen roche oral directacting result research collaboration chugai osaka univer antiviral agent latestage development hepatitis sity codevelope globally roche chugai nucleoside polymerase inhibitor mericitabine genentech actemraroactemra interleukin nere pharmasset protease inhibitor danoprevir receptorinhibite monoclonal antibody approve treat follow acquisition late anadys immune system protein play pivotal role pharmaceutical nonnucleoside polymerase inhibitor inflammation process associate certain setrobuvir danoprevir phase development lip decision autoimmune condition actemraroactemra available mericitabine phase lip decision japan country treat investigate combination interferon ment combination methotrexate free interferoncontaine regimen result phase disease modify antirheumatic drug approve trial inform svr dauphine matterhorn propel treatment systemic juvenile idiopathic jumpc expect setrobuvir currently arthritis japan treatment castlemans disease evaluate phase study combination cur polyarticular systemic juvenile idiopathic arthritis rent standard care roche pegylate interferon pegasys ribavirin copegus strategic agreement roche lucentis file dme merck initiate series clinical trial december fda accept file genentech supple examine novel combination market investigational mental biologic licence application sbla approval medicine chronic hepatitis dynamo phase study lucentis treatment diabetic macular edema dme evaluate combination mericitabine merck victrelis assign action date august sbla base pegasys copegus patient respond result phase iii study rise ride prior therapy begin late show patient receive lucentis experience sig nificant rapid sustained improvement vision compare receive placebo sham injection lucentis ranibizumab vascular endothelial growth factor vegf inhibitor approve fda treatment lifecycle investment point decision commence latestage neovascular wet agerelate macular degeneration amd development lead submission marketing application research development roche business report pharmaceutical division major regulatory approval product clinical datum support filing indication dosage form country avastin ribbon metastatic breast cancer combination xeloda avastin international phase iii data inoperable recurrent breast cancer firstline treatment japan japanese phase data avastin icon gog metastatic ovarian cancer follow surgery actemra lithe year datum rheumatoid arthritis reduction inhibition progression usa roactemra joint damage improvement physical function tender systemic onset juvenile idiopathic arthritis usa switzerland herceptin toga advance herpositive stomach cancer patient japan candidate curative surgery herceptin noah japan noah data herpositive breast cancer neoadjuvant andor adjuvant japan public domain treatment mabthera prima advanced follicular lymphoma firstline maintenance usa rituxan follow induction treatment rituxanmabthera plus chemotherapy rave wegener granulomatosis microscopic polyangiitis usa severe form ancaassociate vasculitis pegasys japanese phase iiiii data chronic hepatitis japan clinical study pegasys prefille pen pegasys proclick autoinjector usa switzerland tarceva saturn nonsmall cell lung cancer firstline maintenance china chemotherapy eurtac publish clinical metastatic nonsmall cell lung cancer epidermal growth experience factor receptoractivate mutation firstline treatment japanese phase datum pancreatic cancer amenable curative resection japan combination gemcitabine xeloda data public domain advanced recurrent stomach cancer patient japan candidate curative surgery xeloxa adjuvant colon cancer combination oxaliplatin switzerland zelboraf brim brim brafmutate inoperable metastatic melanoma usa switzer land brazil metabolism cardiovascular disease coronary heart disease study present major european medical conference support roche compound development metabolic compound safety profile potential slowing athero cardiovascular disease promising compound sclerotic plaque progression novel mode action dalcetrapib treatment coronary heart disease atherosclerosis dyslipidemia dalcetrapib jtt license japan tobacco aleglitazar reduction risk heart attack stroke novel cholesteryl ester transfer protein cetp modulator patient type diabete show raise level good functional high density lipoprotein cholesterol hdlc potentially promote dalcetrapib development update removal cholesterol blood vessel ongoing august roche announce result exploratory phase iii daloutcome study involve patient phase iib study investigate effect dalcetrapib investigate dalcetrapib reduce risk heart atherosclerotic disease progression dalplaque attack stroke patient experience recent vascu lar function dalvessel patient risk acute coronary syndrome roche business report research developmentpharmaceutical division major regulatory filing product clinical datum support filing indication dosage form country avastin icon gog metastatic ovarian cancer switzerland ocean avf ovarian cancer relapse herceptin noah japan noah data herpositive breast cancer neoadjuvant andor adjuvant switzer public domain treatment land japan lucentis rise ride diabetic macular edema mabthera rave antineutrophil cytoplasm antibody ancaassociate switzerland rituxan vasculitis rate fast minute infusion schedule rituxan combination usa chemotherapy treatment nhl roactemra tender systemic onset juvenile idiopathic arthritis switzerland tarceva eurtac metastatic nonsmall cell lung cancer epidermal growth switzerland factor receptoractivate mutation firstline treatment pegasys japanese phase iiiii data chronic hepatitis japan pertuzumab cleopatra herpositive metastatic breast cancer usa vismodegib erivance bcc shhg adult patient advanced basal cell carcinoma usa surgery consider inappropriate zelboraf brim brim brafmutate inoperable metastatic melanoma usa switzerland australia brazil aleglitazar development update neuroscience patient type diabete die heart disease stroke inability control blood roche pharmaceutical pipeline include novel com glucose aleglitazar oral medicine pound development central nervous system disorder potential therapy specifically reduce cardio represent high unmet medical need advanced vascular risk people global phase iii programme investigational medicine phase iii clinical testing alecardio start investigate schizophrenia multiple sclerosis addition aleglitazar reduce cardiovascular morbidity mortality compound early stage development poten patient suffer recent acute coro tial treatment alzheimer disease nary syndrome event addition enrolment com plete phase study alenephro evaluate bitopertin development update benefit aleglitazar people mild mod bitopertin know glyt glycine erate renal kidney impairment reuptake inhibitor codevelope globally chugai phase iii programme initiate late aleglitazar represent new approach reduce cardiovas trial investigate bitopertin combination anti cular risk people activate key protein psychotic treatment negative symptom schizo regulate metabolic signal pathway com phrenia trial patient suboptimally promise peroxisome proliferatoractivate receptor control positive symptom schizophrenia phase alfa gamma ppar ppar ppar activation proofofconcept study bitopertin monotherapy thought increase fat combustion low triglyceride patient acute exacerbation schizophrenia begin increase hdlc good cholesterol potentially slow quarter new class medicine advance atherosclerosis activation ppar improve glu bitopertin potential compound cose metabolism combat insulin resistance type treatment negative symptom schizophre nia addition bitopertin combination current treat ment potential treat suboptimally control posi research development roche business report tive symptom little increase effect novel tion study design detect reduction cognitive decline mode action valuable therapeutic applica provide proof clinical activity blaze biomarker tions psychiatric disorder imaging study design measure change brain amyloid plaque load pet ocrelizumab maintain reduction activity week ocrelizumab investigational humanise mono diagnostic well clonal antibody design selectively target cdpositive treatment decision cell believe play critical role multiple sclerosis ocrelizumab phase iii clinical programme roche invest million swiss franc developing consist study opera patient relap novel diagnostic test platform design provide bet ingremitte multiple sclerosis rrm oratorio ter information treatment decision drive efficiency patient primaryprogressive multiple sclerosis ppm clinical laboratory research centre programme initiate enrol patient trial result phase study ocrelizumab patient rrm common clinical product launch form disease present major medical confer ence october study show significant reduc effort result test new upgrade tion disease activity previously report week instrument device introduce key market maintain week treatment rrm charac table important approval launch terise infrequent acute exacerbation partial help broaden differentiate offering summa recovery attack approve therapy rise treat ppm rare form disease affect screen cervical cancer april food drug administration approve differential target amyloid alzheimer disease cobas hpv test identify woman high risk current research alzheimer disease suggest cervical cancer fdaapprove test iden accumulation amyloid beta abeta peptide brain tifie human papillomavirus hpv genotype hallmark disease main cause loss memory pool result genotype individually patient currently develop monoclonal responsible cervical cancer antibodie design bind abeta help detect disease miss current screening method phase clinical testing represent different approach show athena study largestever diagnos reduce amyloid burden brain tic registration trial cobas hpv test currently pilot sweden primary cervical cancer screen gantenerumab fully human antibody originate research collaboration morphosys bind neu personalise cancer treatment tralise diseaserelevant aggregate form abeta second half mark obtain accumulate plaque brain inter automate molecular test assist tailor treatment fere braincell function phase study positron melanoma colorectal lung cancer patient emission tomography pet imaging demonstrate treat cobas braf test companion diagnostic ment gantenerumab result reduction brain amy melanoma medicine zelboraf approve loid possibly immunological clearance mechanism fda august involve glial cell ongoing phase trial scarlet road cobas egfr test identifie patient nonsmall cell design identify patient early prodromal lung cancer eligible firstline treatment treat substantial damage brain epidermal growth factor receptor egfr inhibitor occur tarceva humanise antibody license immune bind form abeta include plaque brain phase study begin evaluate treatment certification vitro diagnostic product complie patient mild moderate abby cogni requirement use european union roche business report research developmentdiagnostic division major product launch area product description market timeline instrumentsdevice laboratorie cobas clinical chemistry module highvolume laboratorie optiview detection system benchmark tissue stain instrument ultimate reagent upgrade benchmark ultra tissue stainer expedite access slide processing iscan coreo scanner enable digital view tissue slide diabetes accuchek mobile nextgeneration stripfree blood glucose meter care accuchek fastclix oneclick lance device support blood glucose monitor life sciences lightcycler nano desktop unit realtime pcr analysis flx system upgrade sequence instrument kit seqcap choice microarray sequence capture seqcap exome cgh microarray highresolution analysis genomic variation cghsnp cedex bio bioprocess analyser biotherapeutic manufacturing testsassay oncology immunoassay early ovarian cancer detection hpv pcr test cervical cancer screen braf pcr test identify patient eligible treatment zelboraf kras pcr test support therapy selection colorectal cancer egfr pcr test support therapy selection lung cancer dual ish tissue test support diagnosis herpositive breast cancer ihc primary ihc tissue testing include bcl lymphomas erg antibodies prostate cancer pylori precursor gastritis ulcer mlh colorectal cancer breast cancer algorithm analytical imaging software support diagnostic virology hbsag quant immunoassay hepatitis therapy monitor infectious cmv avidity immunoassay help distinguish primary nonprimary disease toxo igg avidity cytomegalovirus infection pregnancy mpx pcr blood screening test detect hiv hcv hbv dpx pcr test detect parvovirus hav human plasma cmv pcr test monitor cytomegalovirus infection hiv pcr dual test detect hiv subtype hcv pcr test measure hepatitis viral load hcv qual quant pcr test detect active hcv infection measure viral load hlab pcr test screen hiv patient hypersensitivity abacavir metabolism vitamin total immunoassay measure vitamin hgh immunoassay supports diagnosis human growth hormone disorder pth immunoassay monitor patient chronic kidney disease maltoseindependent accuchek aviva blood glucose meter test strip chemistries japan gtype hla primer gene sequence primer set research immune set system black type new productfirst market launch grey type new productlaunch additional market asiapacific european union united states worldwide bcl bcell lymphoma gene braf bisoform rapidly grow fibrosarcoma oncogene cgh comparative genomic hybridisation egfr epidermal growth factor receptor erg ets etwentysixrelate gene genome sequencer hav hepatitis virus hbv hepatitis virus hbsag hepatitis surface antigen hcv hepatitis virus human epididymis secretory protein human epidermal growth receptor hiv human immunodeficiency virus hla human leucocyte antigen hpv human papillomavirus ihc immunohistochemistry ish situ hybridi sation kras member ras family oncogene mlh mutl homolog gene pcr polymerase chain reaction progesterone receptor pth parathyroid hormone snp single nucleotide polymorphism toxo igg toxoplasmaspecific immunoglobulin antibodie research development roche business report cobas kra test identifie mutation kras gene cobas analyser stand make broad occur colorectal cancer immunoassay menu available single platform predictive nonresponse antiegfr antibody therapie cetuximab panitumumab bring pcr analysis researcher june roche launch lightcycler nano compact assay run cobas platform offer affordable desktop unit realtime polymerase chain reac unmatched level sensitivity tion pcr analysis genotype gene expression study application nano complement large june fda approve inform dual ish test instrument lightcycler series put realtime pcr help verify patient breast cancer capability reach researcher likely respond therapy herceptin fully world automate tissuebase assay able detect gene central chromosome single tissue slide test allow pathologist easily identify variation ongoing priority gene expression tumour increase accu racy diagnosis test combine roche diagnostic maintain significant investments ihc test companion algorithm analyt develop technology product launch ical imaging software make roche company offer come year effort focus area high ing complete diagnostic workflow solution labora light tory novel biomarker improve monitor hepatitis therapy continue engage biomarker research february quantitative hbsag immunoassay hepatitis pharmaceutical partner draw breadth technolo monitoring receive mark certification test use gy protein genetic tissuebase testing primary elecsys technology measure level hepatitis virus sur focus oncology virology inflammatory cardiovascular face antigen serum plasma enable doctor metabolic disease roche diagnostic collaborate assess sustained treatment success pegasys roche pharmaceutical project include interferonbased medicine help tailor therapy addressing meet expression periostin level individual need page pharmaceutical partner companion diagnostic make blood glucose monitor safe easy september maltoseindependent test strip laboratory coagulation testing accuchek aviva blood glucose meter receive clearance significant investment novel solution test fda new strip crossreact maltose patient blood coagulation hemostatic factor offer increase safety maltose interference plan introduce new instrument mid high rare occasion result falsely elevate blood sugar reading throughput test laboratory comprehen clearance pave way launch new sive assay menu complement lead portable coagu accuchek portfolio november start roll lation testing system use home doctor office nextgeneration accuchek mobile launch acquisition verum diagnostica leader platelet australia netherlands small predecessor function testing strengthen roche coagulation blood glucose meter provide test continuous portfolio tape eliminate handle single test strip allinone diabete care system broaden laboratory offering development pipeline emphasise integrate solution expand cobas series fully automate modular ana facilitate personalise diabetes management reduce lyser central laboratory launch cobas number device step need monitor blood glu clinical chemistry module capable cose deliver insulin solo micropump instance perform test hour module inno feature semidisposable insulin pump patch remote vative reagent manager provide uninterrupted workflow control allow micropump continuously deliver insu highvolume testing follow launch seven immuno lin base patient need schedule launch assay include vitamin total test elecsys test menu addition development distribution roche business report research developmentdiagnostic division key product launch plan area product description market instrumentsdevice laboratorie cobas coagulation analyser mid highthroughput testing benchmark special stain fully automate tissue stainer ventana iscan highthroughput scanner enable digital view tissue slide pointof cobas multiblood lipid glucose pointofcare analyser care cobas blood gas analyser critical care diabete accuchek nano small blood glucose meter require code test strip care smartview accuchek mobile nextgeneration stripfree blood glucose meter accuchek combo insulin pump remote control blood glucose meter solo micropump insulin micropump remote control blood glucose meter testsassay oncology immunoassay early ovarian cancer detection histology ihc tissue test cervical cancer early detection ihc tissue test diagnosis breast cancer gtype tetcbl gene sequence primer set leukemia research kras runx primer set virology cmv pcr test monitor cytomegalovirus infection infectious ctng pcr test detect chlamydia gonorrhoea infection disease metabolism vitamin total immunoassay measure vitamin black type new productfirst market launch grey type new productlaunch additional market european union united states worldwide product initially schedule launch file fda launch soon approve cbl casita bcell lymphoma gene ctng chlamydia trachomatisneisseria gonorrhoeae estrogen receptor genome sequencer human epididymis secretory protein ihc immunohistochemistry kras member ras family oncogene protein pinka pcr polymerase chain reaction runx runtrelate transcription factor tet member tet family oncogene agreement reach dexcom november exclusive partnership dna electronic devel able roche integrate dexcom lead continuous glucose opment electrochemical dna sequencer collabo sense technology future insulin delivery system ration ibm develop nanoporebase single molecule sequencer october roche license technology highvolume dna test arizona state university columbia university develop platform expect directly read sequence nucleic acid single dna combine molecular test women health virology molecule pass nanopore technology blood screening platform bring great automation help advance development project ibm throughput cost efficiency molecular diagnostic bloodscreene laboratory simplify workflow reduce equipment complexity development sche access external innovation uled continue access external innovation target acquisition nextgeneration sequence licensing agreement exchange intellectual property remain focused develop fast effi academic alliance significant mean strengthen cient sequence system enable broad study expand global innovation network col human genome genetic cause disease maintain laboration agreement roche explore ideas research development roche business report world lead scientist translate science clinically global market leader provide customise automation differentiate medication novel diagnostic recent workflow solution vitro diagnostic ivd testing survey boston consulting group measure large commercial hospital laboratory mtm tissue partner function major pharmaceutical company diagnostic company lead portfolio ivds early biotech company rank roche good compa detection diagnosis cervical cancer verum diagnostica nies partner high average score specialise laboratory coagulation testing division attribute particular strength deal structure enter number new research technology flexibility executive leadership alliance management man collaboration include development pcr biomarker ufacture expertise nomination test merck clovis tissuebase companion diagnostic partner survey respondent bayer pfizer automate target enrichment bio medical research calip acquisition licensing agreement academic alliance roche partnering sign new agreement includ e product transaction cover product total roche innovation network expand year research technology collaboration addition thank new collaboration academic institution product outlicense agreement sign special world pre develop academic network team create source open innovation collaborate partner academic institution nation early stage academic institution americas asia europe add lead external partner establish product development partner academic institution expand innovation network ship team main transaction programme umbrella agreement include collaboration ptc therapeutic sma foun hebrew university jerusalem harvard uni dation give roche access firstinclass treatment versity new agreement pende europe spinal muscular atrophy devastating disease effecting chil china collaboration produce tangible dren adolescent lead genetic cause mortal result project bring inhouse joint intellec ity infant toddler acquisition anadys pharma tual property create roche form strategic ceutical bring setrobuvir roche virology pipeline nership cancer prevention research institute usbased company develop ana oral texas cooperation swedish life science initiative smallmolecule inducer innate immunity currenly phase uppsala bio threeway research agreement har clinical trial prove useful treat hcv vard university chinese biotechnology organisation chronic infection cancer addition roche enter biobay agreement evotec germany codevelop commercialise evt compound slow pro inception pre establish translational gression alzheimer disease hubs academic institution academic alliance group operate france canada switzer genentech partnering complete product transaction land netherlands singapore hubs sign new research technology collaboration programme project way yearend agreement support work gre include pre open institute france serve inlicense agreement option purchase single entry point academic collaboration multiple usbased forma therapeutic cover new cancer target disease area scientific discipline similarly transla agreement nominate alliance year tional research hub open zurich foster collaboration vivo lead healthcare industry information provider roche pharmaceutical roche diagnostic inlicense agreement usbased array biopharma add academic researcher swiss federal institute second compound important cancer target chk technology eth university zurich university inhibitor gred development portfolio hospital zurich roche diagnostic sign licensing agree ment acquire pvt probenverteiltechnik germanypvt lab system mtm laboratory ger early verum diagnostica germany pvt roche business report research developmentconducte responsible ethical practice clear policy procedure place maintain safe transparent clinical trial high ethical standard activity include provid e regular ethic training employee clinical trial determine safety efficacy new medi cine clinical value diagnostic test pro employee encounter ethical dilemma work vide critical information costeffectiveness treat resolve colleague contact ment diagnostic test treatment improve quality global ethic liaison office consult internal life information share regulatory authority external expert seek solution office payer order gain marketing approval ultimately receive resolve enquiry reimbursement patient receive stateoftheart care free treatment participant company establish roche scientific ethic rochesponsore clinical trial addition advisory group seag offer advice counsel broad participate medical centre receive educational financial range ethical matter panel meet annually medical support independent external expert appoint roche field genetic bioethic law sociology clinical trial lie member representative patient advocacy group seag provide valuable input roche new preapproval access policy policy provide global number clinical trial approach enable access medicine prior commercial number healthcare approval patient lifethreatene disease centre involve unable participate clinical trial seag advise number patient development principle conduct stem cell phase iiv clinical trial research roche number include patient genentech study initiate prior merger bioethic roche follow strict policy process ensure safety wellbee legal right people participate roche integrate ethical practice scientific research clinical trial include international conference har responsible accountable transparent approach monisation good clinical practice ichgcp guideline development diagnostic therapeutic com ensure compliance standard train monitor pany publish position paper activi audit involve clinical trial include contract tie area genetics stem cell animal research research organisation cro conduct manage trial routinely review update position poli behalf perform trial country cie research involve human animal take plan market medicine test account scientific development public concern maintain searchable database clinical trial www roche charter genetic ensure excellence social clinicaltrialsgov wwwrochetrialscom detail roche responsibility genetic research believe right clinical trial available international fed individual selfdetermination privacy confidenti eration pharmaceutical manufacturer association ality collection use genetic information clinical trial portal national institutes health roche pursue creation genetically identical global registry human being roche ensures share clinical datum encourage stem cell application drug research offer treman scientist publish result work medical journal dous potential establish disease model help identify present scientific medical congress potential novel target screen compound roche con roche scientist contribute scientific publication duct stem cell research inhouse external col include article appear highimpact journal laboration mean improve drug development nature cell science new england journal medicine reduce animal testing potential adverse event research development roche business report roche personalise healthcare personalise healthcare work average patient receive give therapy actually benefit experience effect thank advance new research discipline scientist well understand disease molecular level result able distinguish patient subgroup different cause drive traditionally regard single disease oncology lead effort identify genetic characteristic affect patient response particular therapy identify clinically significant patient subgroup key element personalise healthcare strategy marry new diagnostic technique advance biotechnology effort develop target efficient therapy strategy systematically implement stage new product development roche aim help well understand disease diversity identify difference patient identify good drug target improve quality efficiency effort develop biomarker diagnostic test rroocchhee bbuussiinneessss rreeppoorrtt rreoscehaer pche rasnodn adliesveedl ohpemaletnhctare rochearboxe featuresengindd clinical trial goal establish treatment strategy animal research roche contract research incurable inadequately treat severe disease organisation central nervous system cardiovascular metabolic disor der viral disease roche explore potential mice rat therapeutic use stem cell incurable inadequately treat severe disease rodent rabbit dog animal welfare primate roche longstanding commitment maintain high standard animal welfare public concern animal research seriously possible seek alterna tive use animal computer simulation vitro testing differentiated cell stem cell animal enable researcher produce human antibody immunise laboratory animal animal research remain indispensable biomedical research scientific legal reason regulatory authori roche signatory swiss charter animal welfare tie require healthcare company test safety adopt interpharma association efficacy new drug animal researchbased pharmaceutical company switzerland human roche commit act ethically apply charter commit consistently high standard ani high standard care animal scientific pro mal welfare programme auditing employee train cedure include conform law regulation e stakeholder dialogue promotion approach industry standard management external contractor animal research decrease number animal cro web perform research behalf increase com pare approximately animal roche pharmaceutical diagnostic pipeline wwwrochecompipeline mice rat personalise healthcare wwwrochecompersonalisedhealthcare group policy position guideline wwwrochecom policiesguidelinesandposition animal research clinical trial patient safety wwwrochecomclinicaltrial aspire use animal possible put wwwrochecommanagingmedicationsafety new product technology wwwrochecom risk reliability validity research test result innovationandtechnologie follow approach ethical standard wwwrochecomethicalstandard genetic bioethic wwwrochecomgeneticsandbioethic reduce number animal need animal welfare wwwrochecomanimalwelfare refine tailor procedure minimise pain discom fort replace method involve animal use cell tissue animal roche ethic committee animal welfare spon sore roche award recognise employ ees contractor commitment approach improve animal welfare category labora tory animal care management scientific progress surgery methodology training technique awardwin ning project include development computeraide prediction tool avoid toxicological effect reduce number animal experiment project research development roche business report manufacture site roche business report manufacture procurement manufacture site reliable maintain steady supply medicine test instrument patient health professional world agile support development project new medicine supply global clinical trial study medication ecofriendly reduce emission logistic pilot project switch alternative modes transportation road sea ferry instead air roche business report manufacture procurement key figure manufacture site pharmaceutical diagnostic joint site employee manufacture logistic portfolio medicine test instrument pharmaceutical diagnostic division operate global tinuously build adapt network optimise perfor manufacture supply network play vital role mance well serve product pipeline respond new stage product lifecycle start early product market opportunity change quality regulatory development manufacturing process design divi requirement sion work common aim deliver highquality prod uct meet quality compliance requirement procurement team create sustainable value ensure optimal financial performance regardless world efficient acquisition delivery good service roche product apply set rigorous accordance quality compliance standard safety quality ethical labour health environmental stan team support business unit achieve goal dard roche business base innovation con capture saving reinveste business manufacturing pharmaceutical network pharmaceutical manufacturing network contract manufacturing organisation cmos complement comprise site europe americas asia include manufacturing capability help transition drug chugai site japan employee facility candidate pipeline quickly efficiently different medicine commercial supply outsource phase drug production cmos clinical trial synchronise supply demand global create capacity access specialised capability optimise production planning final delivery medicine cus operating cost roche dedicated team manage tomer synthesise drug substance small mole aspect relationship cmos assure product cule chemically biologic produce quality sustainability operational financial perfor sophisticated biotechnological process employ live mance roche emerge market strategy organism transform drug substance sterile work government partner strengthen drug product vial prefille syrinx solid expand local manufacturing capability order improve dosage product like tablet capsule dualregister access healthcare access emerge country site enable produce key pharmaceutical page product site reduce risk supply interruption well balance production roche global leader biopharmaceutical production capacity approximately global biologic production capacity roche business report manufacture procurementmanufacture site roche group mannheim kaiserb aua gse stl penzberg graz rotkreuz burgdorf segrate reykjavik clarecastle hillsboro vacaville south san francisco indianapolis brab legans utsunomiya oceanside tucson florence shanghai fujiedaukima toluca puerto rico singapore rio janeiro biologics drug small molecules sterile drug solid dosage pharma substance drug substance product drug product assay diagnostic instrument diabetes care december reagent draw decade experience biologic manufacturing objective performance manufacture organi challenging process involve use living cell sation primary objective support roche highly sensitive slight change envi grow pipeline improve manufacture net ronment factor nutrient solution time work process maintain strong focus equipment determine yield amount unwanted supply chain reliability product quality continue product structure active ingredient foster culture continuous improvement share well produce process step illustrate practice site improvement introduce include continue follow production copy biological additional common standard produce small molecule product biosimilar support regulatory activity help site performance transparent ensure bring market safely effectively establish good practice material flow productive biosimilar maintenance biologic production improve scrap handling practice result low manufacturing cost manufacture procurement roche business report high yield improve manufacturing process fda approval zelboraf illustrate effectiveness product pulmozyme nutropin integrate global manufacturing network basel switzer land provide drug substance segrate italy finalise pro support pipeline delivery pharmaceutical manu duction legan spain package drug facturing support development project new medi cine include supply investigational product investment invest new facility upgrade approximately global clinical trial involve ten execute major engineering project thousand patient notable effort ensure meet grow global demand medicine accelerate development manufacturing process prepare future product launch continue melanoma medicine zelboraf rapid scale transform manufacturing facility solid dosage form chemistry innovative tablet formulation base shanghai local global supply operation early microprecipitate bulk powder help roche develop facility receive fda ema approval produce launch zelboraf year start clinical xeloda market approval trial include make available patient day issue international company china biotech production process process step perform sterile temperaturecontrolle condition extensive testing process assure product quality cell line culture fermentation purification formulation filling packaging specific human gene production cell cell culture trans protein separate drug substance insert bacterial remove master ferre progressively biomass cell mulate stable do mammalian cell create cell bank cultured large bioreactor special culture medium waste age form sterile liquid unique master cell line liquid growth medium nutrient medium add product lead powder fill vial yield target ther transfer large f unique composition pure solution centri syrinx pack apeutic protein mas sels cell multiply optimise cell fugation purification ship ter cell bank frozen line enable produc concentration step storage tion desire protein specific desire drug substance protein roche business report manufacture procurementin june roche complete expand penzberg germany majority instrument test manufacture million swiss franc project upgrade expand inhouse allow maintain cost quality advan site therapeutic protein development production tage leverage proprietary technology special exper capacity project entail renovate building tise general use external manufacturer access intel add production lab facility biotech manufacturing lectual property unique technology enable focus development november complete construction core competency optimise efficiency cost new technical facility basel cost million example outsource production handheld blood swiss franc facility house labs offices smallscale glucose meter large work station consumable production line develop innovative process technology turn active ingredient tablet objective performance reorganise operation capsule injectable medicine diagnostic division establish single integrate function drive excellence manufacturing supply chain challenge agility resilience supply chain management procurement global supply chain test march disastrous pursue agenda deliver cost saving build earthquake japan interrupt chugais utsunomiya opera ing capability sustainable high performance quality tion september fire damage site cost supply reliability realise aggre segrate response roche chugai immediately set sive costsave target contribute division supply chain taskforce work close cooperation overall improvement profitability advance health authority ensure continue product supply performance initiative regulatory compliance site fully recover asset management invest facility expand incident resume production capacity alleviate bottleneck mitigate supply risk transfer product manufacturing consolidate capac operational excellence operational excel ity increase utilisation reduce cost consoli lence programme announce late ongoing date supplier base ensure optimal alignment evaluation manufacturing network divest techni external supplier internal capacity cal development small molecule manufacturing operation rightfirsttime manufacturing introduce systemwide locate boulder usa corden pharma corden con programme improve performance systematically elimi tinue supply commercialscale peptide chemi nating error drive improvement rightfirsttime rate cal active ingredient important medicine sell quality cost site programme serve clinical plant oceanside usa gilead sciences forum share good practice network ongoing programme consolidate clinical process devel design quality manufacturability develop tool opment operation divestment mea methodology ensure establishment robust sure lower number people employ pharma production process apply product develop ceutical operation ment project division expect change pay dividend form improve quality manu facturability new product bring market diagnostic support pipeline delivery investment diagnostic network diagnostic operation network comprise operation maintain reliable supply grow manufacturing site global supply hubs europe increasingly diverse portfolio instrument assay includ network handle aspect procurement ing product launch table meet manu facture logistic broad portfolio diagnostic grow global demand support launch diabetes care product portfolio include invest facility equipment undertake test use associate instrument translate major capital project include build pro duction different instrument range large compounding filling facility mannheim germany work station handheld meter reagent kit expand cell fermentation facility penzberg reagent control component consuma production immunoassay ble pipette cuvette dedicated function pro vide quality regulatory support global operation operational excellence operational excel network lence programme consolidated diagnostic oper ational function site second half manufacture procurement roche business report reduce logistic environmental footprint alternative mode transportation canada frankfurt amsterdam kaiseraugst kaiseraugst athens rio janeiro carbon dioxide emission switch transportation product air freight road sea transport reduce emission roughly pilot project begin transfer chemical raw material ana pharmaceutical diagnostic division contin lytical service mannheim penzberg start ued invest quality system address change regu set infrastructure instrument production blood gas latory requirement take proactive step drive sus electrolyte monitoring system rotkreuz switzerland tainable quality compliance manage risk include support production graz austria globally harmonise quality system activity transfer production insulin delivery system endtoend quality management programme roche burgdorf switzerland mannheim track pharmaceutical continuously optimise production pro cesse strengthen product quality oversight supplier quality compliance cmos patient right safe medicine reliable diag pharmaceutical operation successfully manage nostic test result robust comprehensive quality man site inspection health authority worldwide agement system design comply relevant law diagnostic operation pass inspection regulation base recent quality norm standard include cgmp ich iso collaborate health authority industry group provide thought leadership technical quality requirement roche example serve expert con cgmp current good manufacturing practice ich international sultant fda set approval standard medicine conference harmonisation technical requirement regis label use companion diagnostic test roche tration pharmaceutical human use iso international organi zation standardization help advance understanding use good manufac roche business report manufacture procurementture practice activity chair joint fdaemapda ich implementation conference host training session health authority inspector biologic drug substance aseptic processing facility addition provide input guidance docu ment propose regulation law green logistic roche commit incorporate sustainable business practice area supply chain improve process mean ensure patient safety product quality pharmaceutical division establish green logistic project reduce environmental footprint transpor tation raw material finish product project include pilot study alternative mode transpor tation notable change air freight refrigerate road sea ferry transport coldchain prod uct ship switzerland greece change reduce carbon dioxide emission roughly package significant insulate material long require similarly diagnostic division realise significant reduc tion emission alternative mode transpor tation innovation package example emission reduce shipment france switch air freight truck sea transport italy change road transport rail cut division emission emission freight ship ment germany great britain cut temperaturecontrolled trailer year tracking reduction emission waste production energy usage logistic reveal challenge datum availability quality include difference methodology roche site measure energy usage work develop reliable method collect consistent datum organisation information environmental stewardship page manufacture procurement roche business report rroocchhee ppeerrssoonnaalliisseedd hheeaalltthhccaarree roche making personalised healthcare reality researcher globe make enormous progress understand disease root cause knowledge lead dramatic increase identification biological target fight disease roche combine strong inhouse research capacity knowhow late external advance science identify potential drug candidate biomarker pharmaceutical diagnostic roof roche crucial edge come diagnostic research assay technically validate clinically validate ivd assay ivd assay integrate knowledge pharma ceutical diagnostic division efficient way draw process develop target early research approval new therapy diagnostic test medicine use patient close crossdivisional pharma research development commercialisation cooperation scientist distinguish roche company rroocchhee bbuussiinneessss rreeppoorrtt mroacnhuef apcetrusroinnga laisnedd hroecaultrhecmareent rochearboxe featuresengindd procurement procurement key operating function roche pro audit critical supplier compliance sustain curement team work closely roche business unit ability requirement conduct audits help achieve goal capture saving direct spend area audits service provider reinveste business team carefully manage expen audits conduct china india russia eastern diture party include direct expense item europe majority supplier audit meet exceed raw material active pharmaceutical ingredient minimum sustainability requirement audit finding instrument component spare part contract manufac require corrective action relate mainly labour condition ture indirect expense service temporary health safety excessive work hour continue work labour travel credit card laboratory supply closely supplier concern ensure corrective action take offer training sustainability awareness pharmaceutical division finish centralise pro mitigate risk information environmental curement function form departmental group stewardship page single procurement team simplify process align strate gy leverage buying power diagnostic psci member adopt unified procurement team establish structured process sustainability audit protocol protocol set minimum stan major direct indirect expenditure shift glob dard enable sharing audit finding reduce ally align approach local execution expect gen duplication audits supplier start share erate cost saving large purchasing volume selfassessment report psci member strong strategic relationship supplier pilot joint supplier audits new psci protocol roche realise significant saving direct indi rect expense particularly temporary labour conference web event travel negotiate global corporate credit card agreement implement gen roche product portfolio wwwrochecomproduct biotech production wwwrochecombiotechnologyproduction erate substantial saving pharmaceutical supply chain initiative wwwpharmaceuticalsupplychainorg supplier engagement wwwrochecomstakeholderengagement supplier code conduct wwwrochecom partner supplier rochesuppliercodeofconductpdf seek build mutually beneficial relationship sup plier encourage supplier continuously improve work cost reduction financial stability ensure integrate risk management reduce combined environmental footprint demand ethical behaviour promote innovation require supplier commit sustainability prin ciple roche supplier code conduct code incor porate principle pharmaceutical supply chain ini tiative psci roche found member set standard ethic labour health safety environment relate management system addition educate employee way encourage sustainability supplier manufacturing procurement roche business report patient receive treatment innovative roche medicine roche business report marketing distribution demonstrating value collaborate payer stakeholder develop systematic method evaluate cost efficacy new medicine diagnostic improve access continue pilot differential drug pricing programme lead roche therapy egypt brazil china emerge country strengthen healthcare work government organisa tion strengthen healthcare system education healthcare professional support hospital infrastructure improve outcome fund programme increase awareness understanding disease improve screen early diagnosis foster treatment compliance rehabilitation roche business report marketing distribution key figure core marketing distribution expenditure roche group millions chf cer sales pharmaceuticals millions chf cer sale diagnostic millions chf cer sale decrease tight cost management saving operational excellence programme increase reflect high launch cost business area increase distribution cost follow earthquake japan constant exchange rate average fullyear employee roche group pharmaceutical diagnostic answer demand medical innovation improve demonstrate value patient access healthcare challenge require cooperation different segment society break focus medical value product start through science enable roche improve live early stage development objective com patient transform delivery medicine truly mercialise medicine diagnostic test effective identify meet differ improve length quality patient life bring need patient customer collaboration clear medical economic benefit healthcare system partnership society approach increase emphasis regional local work closely payer demonstrate value activity deliver value improve access maintain high product service turn gain appropriate reim standard patient care safety objective deliver bursement market access collaborate innovative pharmaceutical diagnostic offer signifi authority policymaker develop health technology medical economic social value exist option assessment htas model systematically eval uating cost benefit efficient use new medicine patient seek well healthcare diagnostic aim sustain medical innovation meet option well access healthcare market access medical need help address mount pressure strategy address need focus grow healthcare budget demand emerge develop market effective ness strategy reflect strong sale growth example order attain appropriate reimbursement key roche medicine diagnostic despite challeng new oncology test identify patient carry ing condition market mutate braf gene german affiliate roche diagnos tic prepare comprehensive hta demonstrate information performance product prove performance roche test compare find business review page finance method hta show switch test few report annual report page false result improve treatment outcome patient reduce cost payer laboratorie roche business report market distributionsimilarly diagnostic division affiliate collaborate reduce limit growth healthcare budget face national institute health clinical excellence mount pressure public finance nice provide input institutes establishment diagnostic assessment programme goal pro access develop country mote rapid consistent adoption diagnostic test develop country advanced healthcare sys clinically costeffective improve treatment tem people afford treatment patient choice evaluate diagnostic potential insurance able pay treatment improve key clinical decision fully reimburse roche join stakeholder early cofound recognise disparity roche maintain number green park collaborative gpc international initiative patient assistance programme improve access explore feasibility develop guideline medicine united states example genentech access design clinical study meet need hta organi solution help insured patient navigate complexity sation payer expect programme improve health insurance cover outofpocket cost associate relevance clinical research accelerate patient access medicine genentech access care new drug technology foundation gatcf provide free medicine patient uninsure render uninsured meet certain finan furthermore actively participate joint initiative cial medical criterion genentech access solution tween pharmaceutical industry santsuisse asso helped fully insure underinsured ciation swiss health insurer develop basic principle insure patient access issue gatcf pro future htas switzerland reach consensus pro vide medicine uninsured patient posal valuation health technology objec need product tive improve quality transparency healthcare system increase efficiency reduce access emerge country cost demand healthcare service grow worldwide emerge country infrastructure funding need meet demand vary considerably improve access healthcare sustainability healthcare system roche actively support government emerge country effort access remain systemic cause healthcare inequality strengthen public healthcare system strategy focus require cooperation government healthcare provid run local clinical trial work accelerate regulatory er medium patient group company nongovern approval support market development fund pro mental organisation roche commit make contri gramme raise disease awareness collaborate devel bution effort working stakeholder enable ope appropriate treatment policy provide education improve access healthcare associate services globally train healthcare professional activity seek sustainable effective way expand access med help develop healthcare infrastructure icine diagnostic tackle wide problem lack disease awareness low use diagnostic limit cost medicine low rate diagnostic testing healthcare infrastructure budget order improve barrier treatment emerge country improve health condition generally affordability reach people need conduct ing pilot programme differential pricing treatment continue work payer establish cancer hepatitis chronic illness commercial arrangement improve access prod arrangement sell product public healthcare uct include flexible option volumebase dis system price lower establish market return count price cap cost sharing pay performance assurance product reimbursement exploring maintain patient assistance programme help effectiveness access model include people obtain insurance copay support instance discount scheme drug prescribe public partial supply medicine start continue treatment healthcare system patientfocuse solution particularly important second brand government contract maintain access product financial contracting local company fill package distribute crisis government seek brand marketing distribution roche business report topselle pharmaceutical millions chf product mabthera avastin herceptin lucentis pegasys rituxan sale growth cer active substance rituximab bevacizumab trastuzumab ranibizumab peginterferon alfaa indication nonhodgkin lymphoma colorectal cancer breast herpositive breast wet agerelate macular hepatitis chronic lymphocytic cancer nonsmall cell cancer advanced degeneration macular leukemia rheumatoid lung cancer kidney positive stomach cancer edema follow retinal arthritis ancaassoci cancer ovarian cancer vein occlusion ate vasculitis glioblastoma constant exchange rate average fullyear sale lucentis market outside united states novartis roche business report marketing distributiontopselle diagnostic millions chf accuchek aviva nano cobas cobas cobas taqman ventana ihc reagents product accuchek cobas module cobas modules cobas ampliprep immunohistochemistry monitoring system modular analytic modular analytic cobas taqman situ hybridisation elecsys cobas integra sale growth cer market segment blood glucose monitoring immunoassay clinical chemistry virology hepatitis advanced tissue stain hepatitis hiv business area diabetes care professional diagnostic professional diagnostic molecular diagnostic tissue diagnostic marketing distribution roche business report seek partnership government emerge coun china woman herpositive breast try develop tailor programme cancer receive herceptin address challenge meet local pricing service distribution participation need limit access treatment roche china start objective sustainable business model balance programmes association chinese governmental institu need stakeholder commitment improve tion nonprofit organisation include improve access emerge market test quality run patient education pro gramme august work cancer foundation pilot differential pricing programme china establish patient assistance programme eli lead therapy egypt brazil ukraine china gible patient pay half treatment cancer country egypt programme include local pack foundation support roche provide sec age brand alternative formulation pegasys ond half ensure woman receive benefit treat hepatitis treatment egypt topselle ment early see significant market patient receive treatment crease number woman gain access herceptin work brazil government roche nego tiate discount mabthera drug treat patient access develop country nonhodgkin lymphoma condition drug world develop country ldc suffer high reimburse previously mabthera available est level disease weak healthcare system patient cover private insurance pay outof face large budget constraint critical shortage health pocket result significant expansion access care professional facility low level reach patient stand cause prevention treatment disease access healthcare programme highlight detail available website people reach rural south patient receive free medicine child support african africa transnetphelophepa genentech access country india monitor healthcare train inception care foundation diabetes partnership novo nordisks change diabete child programme infant test hiv country roche file hivaid technology agreement amplicare initiative enforce patent medicine reach company ldc ssa country onsite technical help manufacture generic version roche hiv medicine saquinavir month secondment grant treatment course antiinflu healthcare professionals partici employee contribute skill enza medicine tamiflu donate pated pilot online university course expertise help difference country need oncology educare initiative health service ldc ssa country partnership iaea roche business report market distributionto address inequality use expertise support provide valueadde service modernisation healthcare system donate money form programme partnership provide research development innovative medicine diag sustainable patent pricing policy nostic cornerstone contribution tackle research disease high unmet medical need healthcare challenge believe education training knowledge transfer capacity building responsibility lead healthcare company help patient holistic approach healthcare establish operating programme action provide numerous valueadde service scope single entity reason roche collaborate develop healthcare infrastructure raise disease awareness local government nonprofit organisation host screen programme educate healthcare profession company deliver healthcare patient facilitate al provide patient support network experience exchange education healthcare profes sional emphasis local engagement work government payer increase healthcare productivity efficient use financial partnership novo nordisk change resource service support negotiation diabete child programme expand country payer price drug test override con addition india ethiopia kenya approxi cern help people well fast remain healthy live mately child enrol programme long productive life provide insulin diabete care supply basic education training family healthcare work increase healthcare awareness er date clinic establish health healthcare awareness education important care professional train patient wellbee proper medical diagnosis treat ment mind publish newsletters magazines amplicare programme start diagnostic division periodical aim help people healthy choice continue supply hiv viral load test low prevent disease activity include organise dis possible price ssa country country south ease awareness campaign association patient groups america asia work health ministry local hospital conduct screening programme fund agency secure financing amplicare early campaign seek increase gen infant diagnosis hiv initiative yearend partici eral awareness advance early detection dis pat country selffinance programme ease breast lung colon cancer rheumatoid access global fund resource arthritis hepatitis osteoporosis diabete party funder remain dependent unitaid fund addition renegotiate funding agreement organise multidisciplinary workshop ovarian clinton health access initiative global healthcare cancer rome national observatory womens organisation aim strengthen integrate health system health patient group acto attendee include develop world expand access care treat national regional authority representative regional ment hivaids malaria tuberculosis institution scientific society clinician medium event highlight need increase cooperation patent fundamental requirement business model stakeholder establishment centre excellence invest complex expensive risky process great awareness understand ovarian innovation aware patent present cancer include importance regular medical check barrier provide basic medical care up world poor country reason roche file new patent enforce exist patent roche me roche cooperation patient association argen icine disease ldc define united tina publish reflejos del alma reflection soul nation lowincome country define world increase awareness breast cancer book tell story bank file enforce patent antiretroviral hiv woman breast cancer demonstrate medicine hardhit subsaharan african ssa coun possible face disease positive attitude try consequently generic version roche medicine life go breast surgery chemotherapy andor produce distribute country radio therapy possible relapse book message apply license hope reach thousand woman argentina marketing distribution roche business report valueadde service develop health run rehabilitation education material session run disease offer therapy awareness campaign adherence program promot tylt thr aid inis foe mse people patient host screen organise patient program support program provide codevelop education training economic model healthcare professional payer collaborate enable clinical therapy guideline trial participation establish healthcare support manage network care program strengthen hospital establish patient registry lab infrastructure breast cancer leading cause female cancer mortality event demonstrate food exercise impact blood new case year glucose level roche fund diabete hand foundation big blue test awareness campaign year world diabete day roche diabetes care con inforce importance exercise manage diabete duct numerous campaign raise awareness encourage people action prevent diabete activity offer patient support resource include blood glucose screening campus produce information patient family member public venue germany switzerland france spain italy caregiver help understand disease treatment accompany workshop healthy food sporting option proper use product maintain web roche business report marketing distributionsite provide late information diagnostic test contribution patient organisation treatment option include monitor manage poten tial effect website serve portal resource disease awareness centre patient support programme provide access general education train nurse strategy live disease workshops seminar addition operate counselling centre telephone help meeting line coordinate service improve treatment compliance educational rehabilitation grant treatment adherence online resource include wwwaccuchekconnectcom project offer personal discovery tool resource live diabete clinical evidence case study healthcare professional osteoporosis preven world provide forum discuss tion care wwwbonivacom support roche prescrip trend challenge healthcare advocacy tion therapy boniva safety information myboniva program personal resource centre help compli july hold rheumatoid arthritis advocacy training ance similarly wwwherceptincom offer guidance workshop patient group provide support treat herceptin herpositive breast patient group attend parliamentary event gastric cancer information financial support help raise awareness social economic impact resource disease work patient group roche continue longstanding collaboration euro patient group important partner roche pean patient network medical research health egan insight challenge face patient family hold seventh joint strategy workshop patient share interest help patient understand organisation health authority academia industry ask manage condition change role patient group ing improve patient involvement stage patient passive active informed user research clinical development roche egan trans increase level engagement late workshop discussion strategic recommenda tion reality transparency essential endeavour publicly declare patient group relationship provide short further professional development description activity website acknowl help healthcare professional improve patient care pub edge financial nonfinancial support guide lishe broad range education training material european federation pharmaceutical industry asso disease treatment option safety concern product use ciation efpia general healthcare topic addition medical team organise symposium educate support physician variety channel collaborate education example establish virtual medical conference training material service develop glob connect annual meeting american society ally adapt administer locally cultural sensitiv clinical oncology asco world large clinical ity language preference provide financial support oncology event asco attract thousand healthcare pro project mutual interest benefit area fessional learn late clinical trial research breast colorectal cancer cancer general area cancer support hepatitis world hepatitis alliance european liver patient association provide advocacy interaction healthcare professional aim support meeting individual respond patient exchange scientific information improve use request new therapy zelboraf effectiveness product service reason routinely seek input healthcare professional identify patient advocacy activity roche unmet medical need specific disease area develop host annual international experience exchange clinical trial publication educational material patient organisation frankfurt germany twoday conduct accredited continue education course event attend representative patient group area epidemiology treatment option patient marketing distribution roche business report contribution healthcare institution comprehensive programme oncology patient care management addition work payer education determine economics healthcare plan provide healthcare professional capacity planning costing model assist plan education patient budget general public research manage customer relationship counselling help develop healthcare network customer range patient healthcare profe prove invaluable help healthcare profes sional hospital laboratorie healthcare payer sional share knowledge disease new technology meet diverse range need expectation regard encourage discussion standard care customer seek build longterm relationship professional transparent area diagnostic establish testing laboratory train technician correct use instrumentation run meeting customer need pathology educational course set quality control pro track customer satisfaction regular interval usually gramme ensure reliability diagnostic test result annually biannually benchmarke performance educate diagnostic product improve medical peer industry average survey conduct value assist development testing treatment roche party gauge customer satisfaction guideline improve patient outcome representative knowledge helpfulness visit effectiveness medical support clinical datum dis asean association southeast asia nations tribution quality information educatio cancer stakeholder forum roche announce landmark nal material addition diagnostic division look deli prospective study burden cancer economic time service technical support level social impact asean community involve cancer patient asean country analyse feedback identify appropriate com study wholly support roche conduct munication channel establish sale marketing george institute global health sydney australia plan set target area identify serve tool inform evidencebase policy decision important customer opportunity cancer control planning research prioritysetting improve performance region number country transition team provide educational grant omnia educa transactional sell consultative selling mean tion fullservice continue medical education provider form close working relationship partnership key exclusive focus women health issue grant help customer spain example develop practice deliver educational course cervical cancer hpv year increase understand customer need include report result hpv trial expectation gauge satisfaction service result roche spain receive madrid exce manage care programme financial modelling lente award customer confidence create sustainable apply industryleade expertise innovative think value pharmaceutical company select e develop healthcare network manage care pro award gramme payer hospital establish patient regis try new medicine collect realworld data swiss programme effect roche way sell put effectiveness safety patient compliance payer customer need centre sale dialogue healthcare professional use datum order create value customer roche inform decision treatment budgeting purpose programme custom tailor sale representative competency training coaching framework aim achieve excel manage care programme cancer cham lence valuebased sell continuous improvement pion provide resource healthcare organisation start infield team roche business report marketing distributiondriving commercial effectiveness early stage development carry organisation focus develop innovative medi commercialisation perform joint sale call explain cine diagnostic test majority expenditure value effectiveness product make well direct prove clinical safety efficacy datum clinical decision team host sciencebase generate clinical trial produce article symposium publish clinician training material develop professional publication educational material reli combine reimbursement strategy ability datum confirm commercial effectiveness equally critical roche increasingly clinician france example division codevelope qual seek apply evidence gain clinical trial ity assurance programme testing decrease clinical decisionmake false negative result increase reliability diag nosis result nearly woman france eli addition nontraditional customer payer regula gible herceptin therapy tor manage care organisation increasingly emerge receive target treatment activity like key player decisionmake process regu provide value customer allow well latory delivery patient reason ability address use available resource difficult mimic new audience translate complex datum provide duplicate peer clearly differentiate roche new opportunity marketplace shift sale marketing practice evolve focus primarily educate customer ensure patient safety tient today sale representative deep medi cal knowledge require discuss clinical roche product effective safe data safety profile depth healthcare professional life market medicine drive commercial effectiveness intensive train cause effect priority minimise ing course professional selling skill customercentre sure benefit outweigh risk patient approach build longterm business partnership indicate customer global system place collect datum adverse spain introduce qualitative performance measure event monitor safety profile time medicine ment system representative base sale excellence evaluate clinical study withdraw system mirror commercial excellence department market product proactive safety management plan establish number affiliate offer professional support qualified physician continuously sell skill course professional coaching sale man monitor overall safety risk management plan ager place review approve regulatory authority increase use social medium create opportunity drug safety committee responsible drug safety gov reach patient stakeholder improve effec ernance proactively ensure patient safety com tiveness business follow introduction roche mittee chair roche global head safety risk social medium guideline social medium advisory management chief medical officer board develop employee training material high light good practice support business goal regularly analyse medicine reference safety datum policy govern use social medium include train basis help identify potential safety risk ing programme employee internal educational skilled people process system place collect campaign raise awareness social medium channel safety information healthcare provider patient use socialmedia ambassador train monitor medical literature extract new relevant fullday class country safety information medicine employee required immediately report issue relate safety collaborate division quality medicine advance personalise healthcare representa tive pharmaceutical diagnostic division adverse event store global safety database increasingly work disease area start review qualified physician select report market distribution roche business report network global professional oversee patient safety approval phase clinical trial market health authority study management roche representative team healthcare provider patient safety information capture drug safety database drug safety operation department submission relevant regulatory authority usually day integrate safety risk management process notification new adverse signal detection signal evaluation drug reaction label change recall action governance drug safety committee promptly submit appropriate regulatory authority complete activity relate merger require link product evaluate genentech roche include implement single set benefit medicine outweigh risk safety process global safety database procedure place promptly inform physician healthcare provider regulator new safety information counterfeit update product label new safety information counterfeit medicine diagnostic product look require inform healthcare provider update advice identical authentic version difficult detect par use medicine strict product recall ticularly patient counterfeit cause illness process ensure withdraw product rapidly death contain harmful ingredient quality safety problem arise quality deprive patient proper treatment ineffective process system regularly audit internally counterfeit create financial burden govern inspect major regulatory authority ment money waste counterfeit relate roche business report market distributionenforcement measure cost result counter manufacturing process difficult reproduce cop feit cause severe damage patient health ies biological product similar identical original biosimilar product consid estimate scale problem vary widely traf ere generic medicine approve base limited datum ficke counterfeit medicinal product include medical regulatory body accept generic device diagnostic widespread affect devel oping develop country world health organiza support development clear regulatory framework tion identify counterfeiting grow approval biosimilar product european medi underestimate danger cite particular problem cine agency establish system unite product toxicity instability ineffectiveness state congress introduce legislative process approv ing biosimilar healthcare reform responsibility prevent control counterfeiting country framework believe regula rest primarily national government international tory authority follow guideline evalua organisation roche cooperate contribute tion similar biotherapeutic product believe effort develop strong law improve enforcement minimum standard ensure similar version educate public train local official goal biotherapeutic product bring market safely prevent negative impact public health cause coun effectively information find manufac terfeit medicinal product implement internal ture procurement chapter page position anticounterfeite measure design packaging biosimilar available roche website label product additionally continue work authority system track trace product roche actively engage discussion provide feed distribution dispensary national regulatory agency develop e appropriate pathway approve biosimilar product membership efpia contribute include biosimilar antibody activity largely con european commission falsify medicine directive ducte association include emerge bio adopt directive aim protect europe pharmaceutical enterprise ebe biotechnology industry patient prevent counterfeit medicine enter sociation america international federation supply chain strong safety measure include unique pharmaceutical manufacturer association ifpma product identification number tamperevident packaging restriction repackage action include step regulatory authority develop market sure reliability wholesale distribution increase scrutiny include argentina brazil mexico peru implement supplier active ingredient strong collaboration directive guidance approval biosimilar prod customs authority especially world custom orga uct chile columbia india country nisation intensify investigative work process develop similar regulation company prevent counterfeit hire investigative action signal strong commitment develop country staff shanghai china plan implement new measure follow guidance principle biosimilar highrisk region latin america middle east continue push harmonise system contribute public policy product verification resolution issue relate sale product internet additionally roche contribute democratic process sharing advocate increase public awareness counterfeit view expertise government regulator help provide information website explains develop effective law regulation policy public risk counterfeit provide contact information health collaborate general area report possible counterfeit assess value healthcare work public health organisation think tank academic biosimilar unlike traditional medicine contain small molecule pro contribute policy development membership duce chemical synthesis biological medical product industry body include european diagnostic manu complex molecular structure produce living facturer association edma advanced medical technology organism unique genetic property sophisticated association advame ebe ifpma efpia marketing distribution roche business report participation efpia assist new ration assurance acknowledge compliance legislation aim strengthen system monitor practice safety medicine particular protect counterfeit medicine ensure patient receive reliable strengthened practice promote information prescription medicine additionally good business practice ensure compliance new gage discussion directive protect personal regulatory requirement transparency especially datum marketing vitro diagnostic ivd product sunshine act united states guideline associa provide input legislative process aim tion british pharmaceutical industry refer modernise rule conduct clinical trial responsible business chapter page conjunction advame advocate regulatory reimbursement reform fda cen web ter medicare medicaid services cms focus speedy fda approval timely cms coverage product wwwrochecomproduct assess value product pricing wwwrochecom payment determination engage united medicalvaluepatentsandprice state congress patient organisation access healthcare overview wwwrochecom accesstohealthcare national health council use ivds enable early genentech access solution detection disease target right treatment wwwgenentechaccesssolutionscom list patient group support wwwrochecompatientgroup right patient plus value diagnostic reduce overall roche clinical trial patient safety wwwrochecom healthcare cost clinicaltrial wwwrochecommanagingmedicationsafety counterfeit wwwrochecomcounterfeite patent biosimilar wwwrochecompatent roche diabete care advocate responsible marketing wwwrochecom businessintegrityandresponsiblemarkete innovative approach personalise diabetes management roche policy guideline position wwwrochecom case study chronic disease management policiesguidelinesandposition stakeholder engagement wwwrochecom stakeholderengagement marketing responsibly ethically pharmaceutical industry govern strict regulation industry guideline sale marketing product world large healthcare company roche take seriously obligation meet high standard rigorous internal process ensure employee adhere law regulation industry code conduct support good marketing practice include uphold ing social responsibility ensure decision healthcare product service transparent open fair consistent process code conduct set standard interact engage healthcare professional goal enable healthcare professional decision independently base relevant datum available deliver great medical benefit patient continuously train staff interact healthcare professional increase awareness understand code conduct industry countryspecific marketing code guideline good practice addition roche use global marketing sale compliance questionnaire help local manager assess compliance awareness responsible marketing practice general manager sign decla roche business report marketing distributionpersonalise healthcare benefit see patient expert investigator physician patient prof henry likyuen chan caroline robert doretha dee burrell insurance executive researcher medical laboratory scientist prof thomas szucs shirin khambata ford jos gilberto vieira personalise healthcare roche business report immediate combination diagnosis therapy monitor treatment success hepatitis infection major step forward increase benefit patient enormously million people infect hepatitis virus percent people live asia predict well early go respond therapy allow provide effective care assurance patient increase compliance therapy result increase desire treatment outcome patient respond able modify treatment increase chance respond benefit modern therapy investigator prof henry likyuen chan roche business report personalise healthcaredirector cheng suen man shake centre hepatitis study director centre liver health chinese university hong kong hong kong china personalise healthcare roche business report exciting time aware enter new era skin cancer treatment skin cancer area high unmet medical need new compound available go improve survival patient stratification target treatment fatal disease represent major step forward step establish screen relevant genetic mutation need learn well combine compound development order maximise impact benefit patient physician caroline robert roche business report personalise healthcarechef service cancer institute gustave roussy villejuif near paris france personalise healthcare roche business report option target treatment give hope well quality life hear word breast cancer devastating word hear frighten sure life go forward give peace know oncologist believe targeted therapy grateful administer treatment improve quality life past year patient doretha dee burrell roche business report personalise healthcareauthor motivational speaker mother grandmother lover life philadelphia usa personalise healthcare roche business report view personalise healthcare way husband resource way make good business sense insurance company personalise healthcare extremely important future simply able afford stick onesizefitsall method provide patient medicine technology roughandready manner professional analysis tell economic medical viewpoint diagnosticsbase optimise therapy hepatitis superior standard treatment strategy insurance executive prof thomas szucs roche business report personalise healthcarechairman helsana insurance group zurich switzerland personalise healthcare roche business report researcher strongly commit drive personalise healthcare forward appreciate distinct advantage pharmaceutical diagnostic roof field oncology particularly helpful involve diagnostic early possible clinical development increase efficiency speed discover develop patient selection marker actual impact clinic important difference patient live order high frequency drug candidate multiple indication dedicate inhouse diagnostic effort require roche clearly large strong industry scientificbiomarker expert shirin khambata ford roche business report personalise healthcaresenior biomarker experimental medicine leader oncology translational medicine roche nutley usa personalised healthcare roche business report tremendous change task personalise healthcare diagnostic service gain relevance rapidly test result integral factor development modern treatment strategy increasingly treatment decision base sophisticated laboratory analysis cover complex disease cancer example modern diagnostic method enable provide precise datum offer reliable basis treatment decision rapid initiation right therapy opti mise use limited resource healthcare system result strategy real winwin sit uation patient society medical laboratory scientist jos gilberto vieira roche business report personalise healthcaremedical advisor fleury laboratory paulo brazil personalise healthcare roche business report employee worldwide roche business report people global roche employ people country worldwide employee work diverse workforce represent nationality percentage woman key position increase line fiveyear goal engage conduct global employee survey roche group participation rate overall align performancefocuse align compensation strategy performance management principle worldwide create strong link company individual performance reward roche business report people key figure women key position track reach goal roche employee worldwide fulltime equivalentsfte employee fte function europe service north america manufacturing logistics asia marketing distribution latin america research development australia general administration africa total total time equivalent fte reflect actual working time time employee example parttime employee work result equivalent time equivalent employee contract type fte versus employee headcount employee fte operating unit regular fte fix term fte time headcount roche pharmaceutical time headcount chugai diagnostic division total roche dedicated translate innovation science engagement turn foster productivity creativity clear benefit patient need highly skilled people worldwide set apart passionate motivated people inspire roche employer choice ability attract engage difference improve health world retain diverse talent ensure continue deliver innovative healthcare solution patient future work achieve develop people level realise potential offering inclusive culture draw diverse skill build great workplace background knowledge employee day identify internal external talent right skillset current future business require people drive business consistently employ ment develop good people roche achieve business goal excel science innovation year year activity improve ability solve problem attract retain well bright mind roche discover innovative solution enhance effectiveness commit maintain excellent workplace performance team leader inclusion support go offer attractive compensation benefit roche business report peopleprovide employee chance develop personally table highlight award received professionally build career gain recognition achievement mark area expertise engage employee roche consistently recognise excellent employer measure great work environment employ range wellrespecte organisation reflect ee actively engage emotionally intellectually steadfast commitment create maintain work cul experience numerous study employee ture embody roche core value integrity courage engagement key driver employee wellbee passion organisational structure aim strike bal well individual business performance rea ance diversity scale reach speed cohesion son constantly seek new opportunity engage enable leverage innovation value chain employee drive innovation additionally roche strategic fiveyear strategic goal achieve employee october roche honour good multi engagement level bring line national employer great place work institute good employer multinational company choose participate inaugural competition medical compa help realise objective carry firstever ny select good employer roche group global employee opinion survey geo select external award recognition rank award roche site exame roche brazil good pharmaceutical company brazil crf institute roche china employer china universum ideal employer roche switzerland employer natural science universum ideal employer paneuropean employer natural science universum ideal employer roche germany employer natural science deloitte good company work south africa standard excellence award fortunes good company size genentech ssf science employer roche basel great place work roche portugal great place work roche group multinational employer great place work latin america region fortune good company work genentech ssf large company work mother magazine good company genentech ssf south san francisco people roche business report conduct site worldwide offer language position achieve roche establish survey give employee opportunity provide man host programme practice well support woman agement candid anonymous feedback variety diverse talent career ics geo questionnaire measure need expecta range basic measure grant parental leave tion desire employee help continue permit flexible work schedule enhance mentor build engagement identify area need inter ing sponsorship programme maintain tie vention additional support employee response rate leadership network provide solid datum infer key finding highlight good practice identify area improvement gender diversity design effective programme topline standpoint survey indicate overall engagement level place slightly pharmaceutical industry bench woman total workforce mark woman line management woman executive groupwide result indicate employee proud work position company believe future success women key position high satisfaction immediate work environment include factor colleague line manager implement initiative attract diverse talent physical working condition facet work life roche branding recruitment activity emphasise diver low score include decisionmake work process sity inclusion additionally roche career portal high employee connection senior leader area light commitment respect empowerment opportu focus initiative sponsor corporate nity example come roche italy executive committee coming month business unit participate diversity work event milan aim connect diverse candidate ethnicity roche continue measure employee engagement gender physical ability potential employer followup survey month interval effort open position leave positioned create deliver engagement initiative require attract retain talent roche affiliate ask report effective ness local benefit programme support roche diver leverage diversity sity strategy use datum identify area realise roche innovation goal work sustain improvement family friendly benefit flexible culture mutual respect integrity trust differ workplace workschedule arrangement improve view perspective freely exchange debate childcare support add local plan appropriate addi refine ultimately leverage valuable scientific break tionally pharmaceutical division diversity action plan through business result place affiliate plan address local need assessment strength opportunitie affil today employee woman employ iate diversity good practice range recruit ee worldwide represent different nationality ment flexible work arrangement people nationality work global headquarters basel revise benefit mobility policy implement new programme example expand opportunity know diverse workforce provide inspiration woman gain international experience seek way innovation future business depend people well assist work parent deliver improve child diverse background bring different methodology idea care service enhance support dualcareer family knowledge workplace spur great creativity launch support programme help partner prove problemsolve unique collaboration assignee find employment host country key area focus increase proportion woman roche management commit highest define role critical business delivery drive significant value great breadth depth responsi executive level increase percentage woman key bility roche business report peoplewe programme support positive worklife balance foster innovation work example family career network form basel help employee combine family responsibility innovation critical roche success talent man career network execute initiative agement approach actively foster generation expre include championing recommendation internal sion new idea review include outline commuting need work parent study summarise good practice strategy fourfold country launch bilingual website attract retain cross section exceptional people life easy work parent basel create inclusive environment foster ongoing dia logue performance feedback roche work ensure gender balance global support employee personal professional development leadership development programme recognise reward outstanding performance participant key leadership programme woman slightly programme roche sponsor numerous annual competition symposium centage female high potential promise employee award encourage creativity spur collaboration prepare leadership position remain stable recognise company innovative thinker actively support promise young people programme provide increase access lead scientist leadership pipeline resource pursue scientific discovery think socie tys future workforce need scientist interact youth child spark understand interest number high potential career science commemorate unescos inter percentage woman national year chemistry bring high potential kid roche day scientist basel present theatri percentage woman global leadership cal play exhibition explain new molecule programme medicine involve regular basis swiss youth researcher special project development effort begin result number female succession candidate position case goal ignite foster viable rise additionally key innovative idea create maximum value patient leadership position roche hold woman customer employee investor end end sophie kornowskibonnet attract talent general manager roche pharmaceutical france appoint head roche partnering assume new hire outstanding people central element role february join roche enlarge corporate global vision employ good talent key executive committee ensure steady stream promise new idea drive innovation roche member catalyst international nonprofit organisation work build inclusive work ability attract engage retain diverse workforce place expand opportunity woman business worldwide continue affect certain vari result roche employee free access able include resource research information advice work competition key talent promote understand awareness diversity change emerge market dynamic organisation internal communication activity rise technology enable flexible working include launch roche group diversity inclusion new working style intranet update diversity section website change worldwide demographic people roche business report response challenge roche continuously develop attract employee staff rate innovative recruitment strategy reflect good practice market condition deploy team talent scout example strengthen talent pipeline critical target new hire group target business school attend key internal staffing rate business event build awareness roche employer external staffing rate choice progressive engage company ensure reach target candidate imple retain employee turnover mente global social medium strategy initiative talent relationship management strategy recognise corporate leadership council international organisa total tion identifie build good practice europe world company north america asia reach maximum number potential candidate roche latin america host career website country roche australia career site draw approximately million visit genen africa tech site attract additional million visit total roche receive application post vacancy register new candidate roche group talent reason leave pool database employee job seeker interested roche employee approximately annual vacancy fill internally encourage employee employeeinitiate constantly identify pursue new career opportunity employerinitiate neutral maintain success develop innovative product aim attract good scientific mind promote leading edge research strengthen innovation network build scientific collaboration academia ini develop employee tiative postdoctoral programme research early development gre pre programme roche recognise develop training employ seek foster advance science emphasise basic fun ee critical personal growth people damental discovery research work perform alongside success company employee lead scientist clear commitment publish successful position prepare future scientific medical journal gre postdoctoral role include leadership position deliver good programme position pre programme possible performance commitment develop project offer active postdoc employee remain steadfast time organisational change employer pay close attention change val ue expectation workforce recognise employee example employee today different attitude roche provide development opportunity employee expectation work flexibly merge range formal technical leadership training work social life continually review policy programme job assignment offer valuable onthe address emerge trend ensure roche job experience offer mentor coach pro remain attractive employer choice current future gramme continue refresh local offering generation wellestablishe market south san francisco basel introduce suite programme emerge market roche china academy shanghai open early roche business report peoplewe supplement classroom training technology leader roche furnish leader skill enable programme webbase simulation vir need excel foster approach leader lead lead tual classroom show table approach ers feature significant mentoring coaching allow manage training investment ensure access executive addition executive committee meet indi development opportunity employee vidually prospective leader review develop ment plan quarterly continue encourage learn development development leader rotate talent organi sation conduct crossfunctional crossdivisional talent review commitment develop leadership skill total training investment vital roche continue lead science innovation million chf globally culturally diverse workforce training spend employee chf global mobility total number training hour million average training hour international experience important contributor employee development future leader encourage shar number postdoc student e diverse perspective improve global business intern manner respect local culture number roche international assignment rise sharply recent year exclude chugai diversity strat egy increase number woman international support development activity encourage employ assignment participate career development discussion manager discussion help guide personal develop ease transition new culture environment ment identify skill train employee need support return home roche assist employee achieve career goal introduce suite family assignment abroad online tool support career development planning activity continuously assess mobility programme include build core competency establish develop ensure support need diverse assignee popu ment focus area provide guidance career path lation go forward maintain effort strengthen stimulate employee development introduce system health safety international assignee wide process online development planning tool family primary concern roll available roche employee manager global health insurance programme lead expa triate health insurer programme offer firstclass current future leader treatment ensure access highquality medical facility leadership succession plan strategic priority regardless location addition implement security continue roche number brief programme assignee family member initiative place accelerate development gen advance assignments highrisk country eration leader example perspective global leadership rotation programme alumnus pro focus harmonisation global desti gramme build impressive career roche nation service immigration support welcome s world hong kong vietnam shanghai spain basel vices house hunting goal ensure consistent san francisco quality experience assignee family regardless destination addition offer comprehensive suite leadership development programme help new prospective lead er progress career include specially design development assessment centre action learn special global project team objective edu cate leader organisation mean people roche business report rewarding recognise ee access supplementary communication material employee performance management annual bonus guide webbase training reward strong performance transparent consistent process encourages fairness continuous feed build educational effort con dialogue development approach ducting workshop ensure people knowl roche competitive compensation benefit programme edge expertise require fully support performance contribute significantly attract retain well orient culture people follow integration genentech focus align remuneration policy process compensation culminate rollout new compensation remuneration aspect roche comprehensive strat strategy global performance management principle egy attract talented people motivate retain current bring common philosophy approach roche employ employee encourage strong performance ee worldwide company total investment remuneration billion swiss franc performance management employee work increase number project association new global performance management task border function site principle roche implement globally align compen important adopt cohesive standard man sation strategy new common approach create strong age reward employee performance link performance reward position employ good progress objective lay groundwork ee share roche success link goal corpo roll roche global performance management principle rate goal promote culture performance growth new unified approach well enable roche innovation maximise scientific business result create strong link performance reward enable roche new compensation strategy establish com manager well differentiate reward strong employee mon bonus system eligible employee annual bonus performance comprise component individual performance formance individual global function region affiliate new programme emphasise encourage con organisation roche group achievement strategic tinuous twoway dialogue employee man goal ager instead formal onceperyear performance evalua tion enable party reach share understand roche employee transition new approach jan objective achievement compensation provid uary bonus payout new approach e frequent opportunity share idea define busi schedule early key objective ness objective adjust strategy advance employee support manager employee adoption prin development employee take ciple approach ongoing training work formance management discussion shop analyse share information gain roche business unit north america pharmaceuticals workplace evaluation roche employee follow implement approach common policy process performance rating calibrate ensure fairness consistency additionally align employee interest share evaluation focus result achieve holder maintain employee stock purchase programme individual team objective meet roche connect employee country result achieve roche value purchase nonvoting equity share discount integrity courage passion leadership com employee country petencie demonstrate eligible participate programme purchasing security worth million swiss franc additionally manager promote adoption roche global performance man employee receive nonvoting equity security agement principle human resource team roche longterm incentive plan senior leader conduct workshop briefing session primary market additionally employ roche business report peoplebenefit implement chris major undertaking roche competitive benefit programme integral reward organisation prime challenge include package roche offer employee typical package ensure align legacy system multiple plat employee protect financially case illness disability form country translate system retirement death offer series suppleman language project encompass virtually roche affili tary programme design improve health wellness ate team member locate world affiliate offer extensive benefit plan november chris reach major milestone roche regularly review benefit programme cer roche north america pharmaceuticals division switch tain reflect evolve need workforce new system minimal disruption january implement benefit plan emerge market chris live country affiliate agency seek align affiliate benefit programme coun try ensure fairness benefit economy scale january roll international sos global assis maintain fair employment tance programme provide employee immediate practice family member access emergency medical secu rity support service business personal travel roche employment policy govern human right labour relation roche site set inclusive roche diligent effort mitigate financial risk associ workplace philosophy exact employment practice ate benefit plan give uncertainty world roche tolerate form workplace discrimination financial market monitor funding status base gender race age skin colour religion marital status major pension fund closely cash injection sexual preference heritage physical mental disability country combination pension plan policy specific roche site tolerate form discrimina change elimination early retirement incentive tion prohibit law regulation country locality continue introduce flexible retirement mod operate el well accommodate diverse need age workforce chief compliance officer monitor implementation compliance policy association network work increase employee awareness manager compliance officer site benefit roche offer series communication ensure appropriate policy programme place initiative promote fair respectful consistent treatment employee example basel site review remuneration fairness external expert achieve good result equal align human resource process pay equal work man woman reality roche new approach performance management directive protection personal datum ensure compensation support operationally safeguard employee information comply rele common human resource information solution chris vant local legislation comprehensive system integrate major human resource process include organisational management compensa respect employee right freedom association tion benefit performance succession talent man collective bargaining desire roche employee agement international assignment management learning represent union work council similar organisa training programme payroll time management tion currently roche employee trade union mem certain country ber belong labour group additionally roche europe forum represent interest chris incorporate good practice genentech employee country goal roche set foundation efficient effec maintain open dialogue employee representative tive organisation streamline standardise simpli time example approach employee repre fye datum management national affiliate bounda sentative council location european level rie implementation advance roche ability operate involve implementation new compensa effectively internationally tion strategy performance management principle people roche business report roche personalise healthcare intervene molecular level thank ultramodern method sequence genome include series innovative technology roche today scientist identify gene involve genesis cancer example braf gene find mutate form case metastatic melanoma aggressive form skin cancer approximately solid tumour receptor grb raf mek ksr erk oncogenic braf erk transcription factor mutation braf gene result abnormal braf protein lock active state lead uncontrolled cell growth survival potentially drive development progression tumour new cancer medicine zelboraf selectively block action alter braf protein cause cancer cell stop grow die turn lead tumour shrinkage reduce risk disease progression extend patient life personalise healthcare strategy future cancer fight infectious disease like hepatitis inflammatory disease asthma disease central nervous system rroocchhee bbuussiinneessss rreeppoorrtt oroucr hpee oppelresonalise healthcare rochearboxe featuresengindd treat employee fairly employment cycle include support affect organisational change operational excellence programme date position reduce roche phar maceutical result programme reduction take place include transfer party change partially offset headcount increase diagnostic division emerge market china continue build capacity capability give increa ing importance market roche end march conclude consultation employee representative body operational excel lence ensure social plan support measure place meet need affected employee measure include severance pay outplacement ser vice counsel access career centre retrain redeployment option web employee wwwrochecomemployee global career portal httpcareersrochecom employment policy wwwrochecomemploymentpolicypdf group policy position guideline wwwrochecom policiesguidelinesandposition commitment employee wwwrochecomcommitment people roche business report community involvement focus give direct effort strategic area emphasis innovation collaboration sustainability exemplified educare programme train healthcare professional oncology subsaharan africa measure impact assess engagement outcome project support advance strengthen process collect outcome information affiliate community redevelopment particular area focus redevelopment project community devastate natural disaster rebuild school haiti pakistan support education partnership unicef switzerland lay foundation new teacher train college malawi house train teacher roche business report approach breakdown give area core business activity roche philanthropic humanitarian work aim leverage innovation collaboration create social project last benefit reason evaluate philanthropic science project impact cost education art direct give area priority humanitarian culture social project science education art culture community community environment seek respond environment need address roche involve ment emphasis place project reflect criterion innovation apply creative effective solution soci humanitarian social project ety challenge large philanthropic giving direct sustainability deliver endure effect dynamic humanitarian social project believe improve resourceconstraine world human service support system effective way collaboration draw strength capacity help build strong healthy community aim respective partner provide support maintain longterm basis outcome provide tangible longterm benefit local resource country adequate people involve healthcare infrastructure delivery system find invest ment education prevention sustainable action guide roche corporate donation solution medicine diagnostic donation noncommercial sponsorship policy activity include continue support philanthropic donation company fully educare programme launch programme support philanthropic entity regis support training healthcare professional subsaharan tere accredited nongovernmental organisation africa conduct international atomic energy forprofit charity additionally donation local agency launch virtual university cancer affiliate direct local purpose enable roche control regional african cancer training network tailor activity local culture need support educare conduct proofofconcept training model e employee engagement allow quick response hour inservice cervical cancer training course require plus enrollee identify training priority pilot member states ghana tanzania uganda preference engage true collaborator zambia early possible stage aim active longterm ner sharing risk commitment investments association albert einstein college medicine achieve project success focus resource select initiate model programme ethiopia enhance cancer project last impact care cancer awareness reduce delay treatment initiative increase capacity deliver basic care improve quality care focus womens reproductive cancer affiliate report annual donation amount programme launch oncology national roche financial group reporting system conference working forum attend close ethio solicit data project outcome number pian cancer care leader practitioner patient benefit disaster relief number health care worker train number classroom con roche employee action charity trust structe act launch disaster relief campaign aid commu community involvement roche business report example indicator measure success category community beneficiarie roche employee engagement infrastructure system change humanitarian individual screen field relief medicine logistics social service centre renovate social consultation student teacher train volunteer disabled child prototype school construct child enrol secondary employee walker raise fund mobile health clinic operation school vulnerable child construction health train disabled child assist teacher training college construct electricity instal day centre mother maternal health community bore hole drill session repair science teacher professional scientist workshop trainers industrial placement student education development workshop child aid tutoring sciencetechnology educational teaching method adopt presentor secondary student conduct volunteer tutor mentor academic research art culture museum visitor roche expert workshop leader creativity workshop establish art science student joint performance commission project music child creativity workshop ongoing museum operation concert audience challenge music community individual family assist workforce volunteer local cultural group sustain environment community service program family counseling session recreation programme establish public site clean list exemplary outcome representative activity roche affiliate globe corporate headquarters nity redevelopment follow devastating earthquake instrument diabetes care supply help treat haiti extensive flooding pakistan employee patient affiliate raise donation core funding roche help build equip oper encourage employee engagement year june eat school haiti school pakistan roche employee worldwide join roche children walk school expect open spring project generate support child need nearly deliver benefit initial school establish employee participate site raise model replicate million swiss franc include match fund roche majority contribution manage locally majority fund continue support allow business unit determine good address programme malawi provide hivaids orphan need community disastrous earth food education skill train walk proceed quake occur japan march colleague enable roche partner unicef switzerland assist chugai initiate emergency support make significant building critical new teacher train college malawi donation japanese red cross help relief april helped break ground college effort gift augmented course tamiflu house train teacher balance walk fund donate health authority help fight influenza individual roche site support vulnerable refugee centre contribute range diagnostic child locally roche business report community involvementsharing knowhow yield lasting benefit strict provide support creative expression material financial contribution roche sup monthly roche jazz event roche port international committee red cross icrc found museum tinguely bird eye jazz club work provide displaced people access clean bring modern inventive jazz community basel water time roche assist million sixth year roche jazz entertain civilian beneficiary seven country cash people performance ensemble kind donation extend annual commitment support icrc community environment key roche success involvement science education community operate maximise effect business found excellence innovation project select manage locally exem science technology essentially aim attract plary affiliate programme positive difference brazil well scientific mind promote leadingedge research turkey strengthen innovation network build scientific collaboration academia support programme roche plant seed grow improve science education draw talent science career programa vizinho legal good neighbour programme engage outstanding young scientist paulo brazil aim transform jaguar local commu nity confront numerous social vulnerability encourage young people choose science career healthy place commitment well future support initiative promote interest natural sciences switzerland fund launch science public facility hour school provide nationwide competition conduct identify daily programme work mitigate social idleness secondary school class great dedication child street end good commitment field natural science culminate neighbour programme develop numerous cultural competition hold roche headquarters finalist earn sport activity build proactive attitude science day basel rotkreuz win class healthcare critical health issue award science week california initiate programme roche see progress september lead sponsor swiss talent measure include social skill selfesteem cultural forum gather select secondary college repertoire well societal interaction good student switzerland europe discuss neighbour programme reach child adolescent future health follow extensive debate young family help child son think tank develop concrete proposal adolescent address emerge healthcare challenge roche turkey deeply engage local community art culture partnership unicef turkey roche turkey support art culture reflection passion participate stars istanbul largescale art event innovative thinking characterise creativity excellence emphasise bright future child giant starshape distinctiveness present roche conti sculpture inspire culture history city nent salzburg festival programme encourage art display istanbul auction raise science student europe explore con money unicef additionally roche turkey portion nection realms series creativity fund raise roche children walk help workshop relate contemporary music performance unicef turkey establish new kindergarten open march pupil age february toshio hosokawa orchestral piece weave dream receive new york city premiere carnegie hall hosokawa composition fifth work roche commis web sione outstanding contemporary composer auspex roche commission donation sponsorship wwwrochecom donationsandsponsorship community programme wwwrochecomsociety roche employee action charity trust httpreactrochecom community involvement roche business report professional employ globally field health safety security environmental protection roche business report environmental stewardship prevention continue foster employee engagement responsibility safety security environmental protection education awareness training minimised footprint introduce new sustainable technology process minimise impact environment improve ecobalance reduce ecological impact employee target improvement level reduce energy use reduce energy consumption emission track reach fiveyear goal reduction roche business report environmental stewardship key figure roche accident rate rar track reach goal energy efficiency tjemployee track reach goal efficiency temployee track reach goal total environmental impact million impact pointsemployee track reach goal protect people environment essential busi idea database include solution simple proce ness roche refer safety security health environ dure like safe method open cardboard box good mental protection approach sense practice operate complex energy management system responsibility methodically issue con guideline ergonomic office seating cerne quality productivity cost efficiency roche responsible care award recognise good con strive continuous improvement pos tributor application practice receive sible economically viable seek sustainable longterm entry award see implementation improvement change behaviour adapt equipment numerous solution find database site recent standard develop innovative pro award cesse organisation audits assessment assess performance compare result improve monitor law regulation internal standard set performance organisation international chamber com merce business charter sustainable development employee engagement train international organization standardization chemi prevention key effective management cal industry responsible care programme employee support programme worldwide team roche site identify risk develop mitigation conduct internal audits year critical chemi plan communicate policy guideline employ cal pharmaceutical diagnostic manufacturing site ee stakeholder audit frequency facility determine risk potential strategic importance past performance believe education awareness train good sitespecific circumstance internal audits stipulate nec way foster employee engagement responsibility essary improvement plant management local conduct regular training session regional officer conduct frequent spot check conference workshop provide online tool local inspection assess compliance standard language employee employee partici pated hour training expect external manufacturer supplier service pro encourage employee identify area improvement vider meet standard ensure periodically review effectiveness management compliance standard thirdparty auditor system retain periodically audit operation suppli ers issue recommendation improvement event wikistyle database good practice unsatisfactory performance terminate con employee regularly share knowledge exchange new tract refuse award contract supplier roche business report environmental stewardshipshe audits site rir correspond number work day lose occupational illness employee year internal audits maintain integrate programme employee consulta followup tion workplace inspection train area time business approach promote strong safety culture external audits empower employee report address followup safety issue expect similarly rigorous policy time contractor encourage safety wellbee employee sell protective equipment recreational direct material supplier activity discount conduct bicycle safety check activity internal followup audits site improve performance recommend improve health safety activity include expand ment follow audit include increase involvement successful driversafety programme roche site line management improve business continuity man include defensive driving technique specific agement detail find chapter manu health check vision hear number site facture procurement pleasanton california usa offer special training ergonomic showroom prevent injury poor use furniture machine equipment safeguard employee property ongoing effort improve workplace safety result decline approximately security number workrelate accident million work hour goal protect employee visitor physical employee report occupational acci asset intellectual property product harm loss dent decrease frequency compare addition separate security organisation man result number lose day increase age issue virus protection overall roche accident rate worsen roche implement travel security help service number report case occupational illness decrease employee family member service case increase include hour hotline professional advice support roche illness rate lose day occupational illness case medical security emergency travel single case cause absence nearly year provide preventive medical security information country city region year overall positive trend occupational accident illness end issue guideline emergency evacuation recognise roche spain receive social expat business traveller safety bonus low accident rate mannheim site receive chemical industry association responsible security activity include attend east care award ergonomic training programme ern europe security workshop istanbul turkey site security officer chief security officer dis occupational accident illness profile remain consis cuss priority issue transportation security product tent slip fall repetitive strain represent counterfeit information security majority workrelate incident major acci dent consecutive year outside workplace health safety employee die tragically summer party employee health safety priority primary organise company switzerland employee objective roche accident rate rar hit fall tree thunderstorm reduce reduce roche illness rate rir rar correspond number work day lose occupational accident employee year roche environmental stewardship roche business report employee safety health ecoefficiency ecoefficiency base concept create good service few resource create roche accident rate waste pollution quantify ecoefficiency eco roche illness rate efficiency rate eer ratio sale expenditure envi number occupational ronmental protection environmental impact point accident calculate accordance swiss federal office case occupational environment foen efficiently increase illnesse sale reduce environmental harm keep growth workrelate fatality expenditure environmental protection lower high workrelate accident eer value ecoefficiency million work hour seek improve ecoefficiency focus primarily reduce material energy consumption reduce waste renewable resource effort protect property result eer improve counterfeit product major risk patient reputation implement number anticounter feite measure continue work authority ecoefficiency rate eer system track trace product distribution dis pensary detail find chapter marketing distribution page sale million chf environmental minimising environmental expenditure footprint million chf environmental commitment sustainable development impact proactively seek employ new sustainable technolo environmental gy process minimise impact environ impact point ment eer ecobalance ecobalance measure demand place earth invest million swiss franc measure ecosystem allocate environmental impact point compare million cost ecologically relevant factor consumption resource million swiss franc raw material water energy impact waste emission air water soil point increase energy efficiency add relate number employee goal reduce total energy consumption fossil fuel enable monitor environmental impact employee electricity gigajoule employee million impact point baseline base level longterm goal reduce energy consumption establish groupwide goal ecobalance employee approximately level allow management roche site establish local strategy objective reduce environmental impact longterm strategy improve energy efficiency aggre well fit individual situation sively substitute fossil fuel sustainable energy goal increase proportion sustainable energy total environmental impact employee use energy use main source million impact point improvement greenhouse gas emission reduce energy consumption target improve ecobalance level lower operating cost energy conservation priority roche business report environmental stewardshipecobalance material primary energy emission air water emission water landfille waste environmental impact employee mio impact point product group systematic approach energy reduce automobile fuel consumption fleet emission management include meet low emission target gkm construct energyefficient building standard set western european pharmaceutical oper retrofitting heating cool air conditioning installation ation reduce fossil fuel electricity consumption adjust range acceptable temperature office recover waste heat building cool system basel workplace develop green programme use low purchasing energyefficient equipment include hybrid energy lead screen consolidate data centre dieselefficient car heat generate heating building change work process recycled sustainably harvest building material review employee travel need renovate office building nutley new jersey achieve leadership energy environmental continue focus responsible use design leed gold certification source continuous reduction energy consumption instal window film building genentech campus activity include usa provide additional insulation block environmental stewardship roche business report energy use type greenhouse gas emission consequence energy saving measure fuel company vehicle greenhouse gas emission equivalent oil grid electricity total emission million tonne fuel business air travel total emission million chf district heating sale tonne waste energy use terajoule natural gas total energy use total energy use ultraviolet radiation infrare heat million chf sale visible light total energy use employee activity result improved energy usage area include reduction business travel relate fuel consumption reduce use halogenate hydrocarbon decrease car fuel consumption halogenate hydrocarbon use refrigerant cool increase use sustainably generate electricity equipment chlorinate compound deplete ozone layer fluorinate partially fluorinate one reduce energy consumption building considerable global warming potential persis stationary equipment relatively stable staffing level tent stay atmosphere long period time overall energy consumption decline energy con plan reduce halogenated refrigerant roche site sumption employee gigajoule employee newly acquire site genentech surpass target gigajoule ventana work separate timeline lower greenhouse gas emission ghg emission haloge greenhouse gas ghg emission roche originate nate hydrocarbon preference eliminate generation use energy goal improv emission recent acquisition lack alter e energy efficiency reduce energy consumption native country complete elimination apply ghg emission reduction measure chemical unrealistic continue tonne employee level examine alternative work refrigeration supplier reduction level expect achieve fur reduction ther reduction substitute fossil fuel energy sustainable source significant progress reduce emission halo genate hydrocarbon eliminate seek decrease ghg emission establish energy halon reduce fully halogenate compound standard ensure new plant building design exclude genentech site maximum energy efficiency optimise retrofit ting exist asset encourage exchange well halogenate hydrocarbon tonne practice variety communication channel reduce fuel use heat cool inventory operate site businessrelate travel emission decline slow rate reduce roche business report environmental stewardshipdecrease air emission plant dispose nonhazardous general waste minimise emission air variety technology authorise landfill practice priority avoid pollutant reduce quantity pollutant control remain pollutant emis increase total production waste gen sion line ecobalance goal overall objective eration go slightly incorporate waste emission low level achieve mitigation measure increase solvent recycling recent year singapore general waste decline mainly low amount construction waste new strategy prescribe continuous improvement pro recycling method south san francisco ponc puerto gramme reduce emission air manufacturing rico operation include flue gas scrubber reduce nitro gen oxides sulphur dioxide incin roche environmental awareness chemical tech eration freeze process reduce release volatile nology react programme award proposal improve organic compound voc reduce energy sustainability chemical process synthese use receive submission replace hazardous chemical avoid waste reduce energy consumption complete pilot study cryogenic equip cut cost win team reduce onehalf ment reduce air emission plan install equipment reagent solvent need manufacture florence site freeze volatile organic com equal product replace hazardous reagent pound waste air emission air fluctuate year previously problematic one year remain low level roche participate technical investigation emission air tonne kesslergrube landfill grenzach germany user site evaluation remediation option ongoing switzerland roche company continue clean voc hazardous waste landfill klliken bonfol particulate nitrogen oxides belleville new jersey usa site roche dismantle sulphur dioxide building study remediation option nutley usa site roche conduct fullscale technical volatile organic compound investigation soil groundwater condition local ise remediation activity complete manage waste way include groundwater treatment soil excavation waste parameter ecobalance waste reduction installation soilvapour extraction system target reflect goal improve group ecobalance maintain waste waste tonne reduction goal individual site set group goal large yeartoyear fluctuation mainly waste construction demolition activity general waste produce roche pharmaceutical diagnostic compa general waste ny produce relatively low volume chemical million chf generate small quantity chemical waste reduce sale low volume waste produce biotech chemical waste product few chemicalbased product neverthe produce accept responsibility waste generate chemical waste operation include deposit past site million chf landfill permit landfilling resort sale inert material slag incineration ash depend availability suitable local wastetreatment environmental stewardship roche business report conserve protect water resource eliminate chemical contain octyl phenol moiety roche support global effort promote water protection process potentially negative impact conserve water reserve improve access clean drinking aquatic life water longterm goal reduce total wastewater toxicity analyse waterrelate risk world business baseline continue council sustainable development water tool iden investigate reliable performance indicator measurement tifie site study determine availabil method establish baseline meantime ity clean water meet future business need strive stabilise water consumption group commission wastewater treatment plant anaerobic degradation penzberg germany capture methane half total quantity water utilise cool generate heat electricity surplus energy feed circuit chemically contaminate analysis site grid building discharge rest purify treatment plant release watercourse result activity water consumption decrease million cubic metre major operate site demand large vol reduction achieve cool irrigation cool ume water area water scarcity adopt conserva weather particularly california tion reduction programme accord local condition need example californian site use drought transfer million cubic meter water resistant landscaping site reduce water con treatment plant result discharge tonne sumption organic matter addition kilogramme heavy metal collect recycle water cool tower create leach metal pipe discharge closedloop system operation watercourse reuse cleaning water rinse recycling water water usage discharge reduce cool requirement improve cool pro cesse improve heat recovery water withdraw million cubic metre record organic emission water total organic car water bon toc treatment wastewater treatment plant million cubic metre discharge wastewater pollutant comply fully wastewater discharge relevant regulation include pretreatment require treatment plant ment elimination rate wastewater million cubic metre treatment plant high seek minimise organic matter contamination water discharge reduce discharge toxic poorly biodegradable sub watercourse stance heavy metal treatment tonne reduce wastewater production heavy metal treat pretreate wastewater ozone discharge case non poorly degradable contaminant watercourse treatment kilogramme method calculate environmental impact ecobal ance include water usage reflect importance reduce total withdrawal overall environmental target activity area water management include collaborate german scientific institute wasserver sorgung langenau establish new indicator meas ure total toxicity wastewater total organic carbon toc roche business report environmental stewardshipsupporte biodiversity evidence suggest exposure trace concentra tion surface ground drinking water pose roche support principle resource stewardship define harm human health risk aquatic life think convention biological diversity cbd great scientific study identify shortterm main goal cover effect exposure lowlevel concentration pharma conservation biological diversity ceutical research conduct evaluate sustainable use component potential longterm impact recognise fair equitable share benefit use need research possible effect support genetic resource scientific work field avoid use noncommodity naturalresource materi als source product discovery development legislation compliance pharmaceutical discover develop com mercial product derive natural plant microbial animal meet local law regulation group pol genetic material use resource guide icie rigorous external standard principle goal cbd fully track registration chemical operate facility protect area material accord european legislation registra area high biodiversity value site require access tion evaluation authorisation restriction chemical city infrastructure urban environment reach requirement globally harmonise system classification labelling chemical pharmaceutical environment consecutive year prior incur sig nificant fine sherelate violation consider entire lifecycle drug step assess small fine minor infraction minimise release pharmaceutical environment respect environmental issue fail comply stage equipment safety regulation incident pre sente significant risk employee local com design manufacturing site reduce risk active munity incident seriously take step ingredient enter wastewater support pharmaceu correct problem prevent similar incident tical takeback programme employ proactive measure occur future additionally fire cause electrical prevent release product environment failure finishedgood warehouse budar hungary way destroy product store hungarian market offer financial incentive ensure unused fire segrate italy plant result overheat date product return retailer powder mill fortunately hurt incident supply chain establish policy require return waste pharma ceutical product incinerate dispose landfill support research effect pharmaceutical environment provide authority environmental risk assessment new medicine trace pharmaceutical product enter environment variety way manufacturing process improper dis posal unused medicine natural process fol low normal patient use patient use generally recognise primary contributor environmental stewardship roche business report roche personalise healthcare personalise treatment strategy infection hepatitis virus hcv cause acute chronic liver damage ultimately lead liver failure cirrhosis cancer liver worldwide million people infect hcv today know number subtype hcv differ molecular structure responsiveness treatment roche develop molecular test identify hcv subtype patient information help physician predict long patient continue treatment week order achieve last virological response start treatment week therapy week therapy treatment stop test week test week hcv concentration viral load reduce significantly treatment stop viral load week reduce slightly therapy viral load reduce personalise healthcare improve physician ability predict response adjust treatment roche personalise healthcare strategy draw advance molecular biology monitor patient response therapy adjust duration therapy patient need administer medicine precisely right time longterm treatment strategy develop new diagnostic test medicine focus efficient way rroocchhee bbuussiinneessss rreeppoorrtt ernovcihroen pmeersnotanla slisteewd ahrdesahltihpcare rochearboxe featuresengindd goal environmental protection education goal basis target date improve energy efficiency goal basis target date gjemployee improve education increase training employee increase share sustainable average hryear energy total energy consumption reduce emission employee safety line improve energy efficiency goal basis target date reduce total environmental impact improve roche accident rate calculate ecobalance accord number lose working day swiss federal office occupational accident environment bafu employee rar rar reduce total waste water toxicity reduce number occupational accident cause lose working day case work hour web environmental protection wwwrochecomenvironment roche illness rate number policy wwwrochecom lose working day safetyhealthandenvironmentalprotectionpdf eer ecobalance wwwrochecom occupational illness factsheetecoefficiencypdf bring number case occupational goal wwwrochecomshegoal performance wwwrochecomsheperformance illness cause lose working day service wwwrochecomsheservice case work hour group fact sheet position policy guideline wwwrochecompoliciesguidelinesandposition wwwrochecompolicyguidelinesandaudit environmental stewardship roche business report foundation year ago roche year specialise leader researchfocuse healthcare combine strength pharmaceutical diagnostic roche business report corporate governance roche commit stakeholder operate business focus value creation innovation management culture conform modern standard corporate governance group policy communicating transparently build basis successful implementation commitment stakeholder remuneration report roche success depend ability dedication people recognition form basis guideline system roche performanceoriente remuneration policy roche business report corporate governance corporate governance roche complie relevant corporate governance agm march board director nomi requirement particular applicable law swiss nate john bell andr hoffmann und franz humer stock exchange swiss exchange directive include election board commentary thereto swiss code good prac tice corporate governance promulgate swiss busi ness federation economiesuisse company internal gov corporate executive committee ernance framework particularly article incorporation bylaw embody principle need ensure erich hunziker chief financial officer chief information offi company business manage supervised cer deputy head corporate executive committee manner consistent good corporate governance include decide retire roche end march necessary check balance board director appoint alan hippe succeed print annual report contain select link erich hunziker chief financial officer mem roche website wwwrochecom reader provide ber corporate executive committee april snapshot company report date direct source consult sophie kornowskibonnet general manager roche time uptodate information corporate governance pharma france appoint head roche partner roche annual report cover single financial ing group headquarters basel join year end december website contain information enlarge corporate executive committee new member permanent nature late roche news february report severin schwan ceo company article incorporation bylaw curriculum roche group vitae member board director corpo rate executive committee publish website succeed dan zabrowski take position head roche apply science diagnostic division locate penzberg germany february dan board directors zabrowski member diagnostic leadership team report daniel oday coo roche diagnostic annual general meeting agm roche holding ltd march shareholders approve shortening information member board director includ term office new director reelection ing year elect year year reelect pius baschera bruno gehrig term end member corporate execu lodewijk vink andreas oeri members tive committee list page board director new term year provide article incorporation walter frey wolfgang ruttenstorfer decide retire member board information relate director paul bulcke peter voser christoph franz corporate governance elect new member board term year provide article incorporation group structure shareholder roche operate business organise divi organising meeting immediately follow agm sion pharmaceutical diagnostic pharmaceuti board director approve committee structure cal division comprise business segment roche committee membership show pharmaceutical chugai genentech segment integrate roche phar maceutical diagnostic division consist follow e business area apply science diabetes care httpwwwrochecomaboutrochecorporategovernancehtm molecular diagnostic professional diagnostic tissue roche business report corporate governancediagnostic business activity carry right share participate available earn group subsidiary associate company detail ing liquidation proceed follow repayment information roche holding ltd significant subsidi share capital roche ne right pertain arie associate company include company thereto include provision protect interest list information domicile share capital equity inter nes holder describe article incor est list finance report note roche porat ion roche holding ltd group consolidated financial statement subsidiarie information debt instrument issue associate outstanding bond provide finance report major shareholder list finance report note note roche group consolidate financial state roche group consolidate financial state ment debt ment equity attributable roche shareholder additional information employee stock option pro relate party page note vide finance report note roche group financial statement roche holding ltd significant consolidated financial statement employee stock option shareholder equity compensation plan andr hoffmann vicechairman board director roche issue option apart employee stock andreas oeri member board director option stocksettle stock appreciation right ssar chairman board corporate governance sustain option issue connection debt instrument ability committee serve respective capacity option award employee debt board committee representative share instrument issue effect holder group pool voting right receive roche share capital remuneration set forth remuneration report finance report note roche group board director corporate executive committee consolidated financial statement relate party information member board director note financial statement roche hold include year elect year ing ltd board executive remuneration term end member corpo lukas duschmal member shareholder rate executive committee list page cur group pool voting right make sixmonth intern ricula vitae information include information ship roche singapore shanghai relation board membership available continuously update ship exist shareholder pool voting right internet crossshareholding annual general meeting elect member board director stagger election capital structure nominee vote separately article information roche capital structure provide incorporation roche holding ltd minutes finance report note financial statement roche annual general meeting roche holding ltd hold hold ltd additional detail contain march article incorporation roche holding ltd exception franz humer william burns change equity detailed finance report note arthur levinson member board financial statement roche holding ltd director member roches corporate execu company share capital swiss tive committee serve executive capacity franc divide fully pay bearer share group subsidiary financial year proceed nominal value swiss franc restric current reporting period tion exercise voting right share internal organisation board director deposit share vote restriction division authority responsibility board authorise conditional capital management remit board committee addition nonvoting equity security nes issue bearer form form share capital confer voting right ne confer httpwwwrochecomaboutrochemanagement boardofdirectorshtm httpwwwrochecomaboutroche managementexecutivecommitteehtm httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm annualgeneralmeetingshtm corporate governance roche business report information control mechanism available detail risk management include risk factor board dealing corporate management gov risk management charter risk management erne bylaw compliance website financial risk management board director roche holding ltd organise specifically describe finance report ensure group business conduct system internal control financial reporting responsibly focus longterm value creation page finance report end roche board delegate certain responsi internal audit bilitie committee composition chair group audit report general counsel direct person january describe access regular briefing audit committee committee authority responsibility define ongoing activity audit report chief audit detail bylaw board director risk advisory executive attend audit committee committee presidium chair inde meeting external auditor pendent director group audit independent appraisal function accord bylaw board director evaluate review group activity service request member board meeting management annual audit plan yearly define chairman present convene roche board focus area emerge market thirdparty manage meet year assess chairman performance ment validate senior management present meeting attend chairman audit committee roche group commit chair vicechairman maintain high standard internal control management information system board worldwide operation management responsible director inform important issue sale assess business risk aspect operation development etc monthly basis board access implement effective efficient process con electronic information platform provide timely trol whilst ensure compliance internal external information board director board com rule regulation mittee system control set forth conduct operational audits group audit determine board director establish system control management response risk surround business continuously monitor audit committee process system evaluate appropriate corporate governance sustainability committee ness completeness efficiency process consist follow element control action plan implement necessary change report operate financial risk risk management enhancement develop busi system nessauditee track completion roche system place identify manage type external auditor risk potentially affect business roche risk chief compliance officer compliance officer sub management charter set approach accom sidiarie panye responsibility pharmaceutical diagnostic safety health environmental protection department division global function conduct formal risk corporate sustainability committee assessment process year develop science ethic advisory group seag issue risk plan material risk monitor relate genetic genetic engineering establish deviation review regular performance dialogue consolidate group risk report include target risk member corporate executive committee profile discuss corporate executive committee invite attend report person agenda approve group business plan item concern situation warrant mem present audit committee process ber enlarge corporate executive committee subject regular review finding present audit committee board httpwwwrochecomcorporateresponsibilitybusinessethic riskmanagementandcompliancehtm additional information provide finance report note httpwwwrochecomaboutrochecorporategovernance roche group consolidate financial statement risk management articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance httpwwwrochecomcorporateresponsibilityenvironmenthtm committeeshtm httpwwwrochecomcorporateresponsibilityhtm httpwwwrochecomaboutrochecorporategovernance httpwwwrochecomcorporateresponsibility articleofincorporationhtm csrresearchanddevelopmentgeneticsandbioethicshtm roche business report corporate governanceboard board committee attendance corporate governance presidium nomination remuneration audit sustainability board committee committee committee committee number meeting humer gehrig hoffmann baschera bell bulcke burns vink franz julius levinson oeri voser weder mauro member committee new board committee member march franz humer invite guest board committee meetings board board committee attendance february retired board member frey ruttenstorfer invite attend board committee invite threeday visit major subsidiary board chairman board corporate executive com committee meet follow mittee member deliver report committee meeting presidium board directorsnomination commit elect commission independent expert report tee meeting approx hour service consultant remuneration committee meeting approx year blackout period impose hour senior employee prohibit trading com audit committee meeting approx hour pany stock follow blackout period effect corporate governance sustainability committee december february meeting approx hour april april june july march board committee partly october october change membership individual participation blackout period change chairman board member committee meeting outline chart board director circumstance warrant reflect attendance old january board director meet meeting february new march com hour length fullday meeting mittee composition figure indicate actual length meeting include remuneration committee member permit contribute director extensive premeete preparation postmeete attend remuneration committee meeting matter concern followup activity deliberate decide corporate governance roche business report board director regularly conduct assessment relationship statutory auditor performance annual general meeting roche holding ltd member corporate executive committee march shareholder vote appoint kpmg maximum ordinary notice period month kpmg statutory auditor base exist legal management contract fall requirement swiss code obligation article scope subsection annex directive maximum term office seven year audi information relate corporate governance tor charge ian starkey replace predecessor john morris auditor charge start business year remuneration shareholding loan information long auditor auditor detail remuneration shareholding loan charge serve capacity provide set forth separate remuneration report page statutory auditor participate audit commit finance report note tee meeting prepare write oral report roche group consolidate financial statement equity result audits audit committee oversee attributable roche shareholder relate party assess auditor make recommendation page list note board information responsibility audit financial statement roche holding ltd board committee article bylaw statutory executive remuneration board executive share auditor participate meeting audit commit holding page tee participatory right shareholder report statutory auditor consolidated finan participatory right shareholder define cial statement financial statement roche article incorporation roche share find page respectively year issue bearer restriction admission finance report annual general meeting exception share deposit specify period date kpmg receive follow remuneration service meeting admittance card issue statutory auditor roche holding ltd audi shareholders provide article tor roche company new include chugai incorporation shareholder elect represent party annual general meeting article incorporation contain restriction exercise vot millions chf ing right quorum requirement stip auditing service ulated conformity swiss code obliga auditrelated service tion tax consultancy service article incorporation shareholder total represent share nominal value million swiss franc request placement item statutory auditor elect year annual agenda annual general meeting general meeting later day date meeting information policy change control defensive measure provide article incorporation corpo article incorporation contain provision rate notice publish swiss official gazette mandatory bid rule swiss law apply commerce daily newspaper designate changeofcontrol clause component board director basler zeitung finanz und wirtschaft remuneration base roche ne terminate lagefi temps neue zrcher zeitung event acquisition vest period restriction roche report halfyear fullyear result business preexisting award remove report publish print online format medium option exercise immediately httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm articleofincorporationhtm roche business report corporate governanceevent addition detail thirdquarter sale fig concrete information material allege violation ure publish year april october roche group code conduct certain predefine current list publication date available english category corporate governance sustainability german internet committee audit committee board direc relevant information document include medium tor inform substantial violation release investor update presentation analyst investor conference available internet fur chief compliance officer report general counsel ther publication order email fax telephone regularly corporate governance sustainabil baselwebmasterrochecom ity committee audit committee board tel directors fax contact address investor relation hoffmann nonapplicabilitynegative disclosure roche ltd investor relation group finance basel expressly note information contain switzerland mention nonapplicable omission tel construe negative declaration provide fax swiss exchange corporate governance directive commentary thereto additional information include detail specific contact person available internet chief compliance officer compliance officer network chief compliance officer compliance officer network commit ensure roche group code conduct consistently comply roche group serve contact person shareholder employee customer supplier gen eral public issue relate implementation compliance code employee party aware violation roche group code conduct bring attention manager supervisor report chief compliance officer ur jaisli direct phone number email ursjaislirochecom disclosure treat confidentially addition end employee anonymously report irregularity com plaint correspond mother language speak hotline addition roche establish business ethic incident report beir system enable chief compli ance officer capture track monitor allege violation initial report local compliance officer resolution business ethic incident record sys tem local compliance officer receive specific httpwwwrochecommediahtm httpwwwrochecominvestorshtm httpwwwrochecominvestorscontactshtm httpwwwrochecomaboutrochecorporategovernance httpwwwrochecomcorporateresponsibilitybusinessethic codeofconducthtm riskmanagementandcompliancehtm corporate governance roche business report remuneration report remuneration report summary help roche employee perform consistently roche success depend ability dedication high level remuneration policy design foster value people recognition form basis remuneration creation reinforce culture performance innova policy system tion apply nonmanagerial employee manager primary aim remuneration policy encourage longterm focus align management inter key principle underpin policy est interest roche shareholder holder focus value creation roche nonvoting equity security ne pay performance enable employee share company success remuneration report submit separately fairness transparency remuneration decision consultative vote annual general meeting balanced mix long shortterm remuneration remuneration corporate executive committee mem component ber senior roche executive comprise market competitiveness base salary fix base salary remain change exception daniel oday base salary base pay bonus block nonvoting equity security bonus variable corporate executive com ne award stocksettle stock appreciation right mittee bonus provide cash payment ssar performance share plan psp support nonvoting equity security block principle remuneration component link year block period accord corpo company financial performance commercial success rate executive committee member individual decision align interest roche employee stocksettle stock appreciation right ssar vari shareholder able performance share plan psp award variable separate component remuneration psp ne award individual member corporate executive committee ssar grant strike show individual description remuneration price ne price december corporate executive committee report time value recipient change roche future ne price improve base pay change base remuneration base pay cash payment level determine accord board director market datum world big pharmaceutical compa ny specific position individual employee ability rest report detail experience performance time pay increase link individual performance account remuneration policy prevail market condition company overall eco roche fundamentally renew remuneration policy nomic situation base pay pay increase conclusively review reconfirm key principle monitor determined remuneration committee framework employee policy aim motivate retain current employee attract talented new one bonus bonus award recognition individual contribution value creation normal job expectation stocksettle stock appreciation right ssar page finance report note roche group consoli date financial statement relate party note peer set abbott laboratories amgen astella astrazeneca financial statement roche holding ltd board bayer becton dickinson bristolmyers squibb eli lilly executive remuneration board executive shareholdings glaxosmithkline johnson johnson merck novartis pfizer page sanofiaventis takeda roche business report remuneration reportvariable remuneration element bonus ssar psp relation fix base pay member corporate executive committee bonus ssar psp individual target value assess max consideration performance base annual base pay competitor measure january macroeconomic development year cycle relation value base pay minimum maximum relation value base pay cash payment value development value development block ne determine determined performance ne performance ne grant grant performance criterion group objective group individual contribution group performance divisional business remuneration tsr relation performance committee decision tsr performance individual objective discretion peer set consider profit page sale growth opac operate profit capital charge split group objective individual objective mean incentive create strengthen performance share plan psp new business opportunity strive outstanding result member corporate executive committee bonus amount link group divisional business member senior management currently individu formance consider profit sale growth opac operating al worldwide participate performance share plan profit capital charge performance achieve psp psp establish period ment individual functional measurable qualitative year base threeyear comparison performance objective reason competitiveness roche total shareholder return tsr compete company disclose detail individual objective mem overlap performance cycle ber corporate executive committee remuner psp psp psp ation committee board director define psp close december term corporate executive committee member bonuse decem performance share plan determine annually board ber base mention objective cor director act recommendation remu respond result achieve neration committee stocksettle stock appreciation right ssar detail psp calculation additional infor stocksettle stock appreciation right introduce mation set forth remuneration member cor january establish uniform system remu porate executive committee performance share plan neration roche ssar entitle holder benefit psp financially increase value roche nonvoting equity security grant date exercise date remuneration board director awards allocate individually remuneration corporate executive committee committee decision discretion detailed informa year remuneration committee board direc tion available page tor set remuneration member board direc remuneration report roche business report tor corporate executive committee cash payment bonuse remuneration chairman board bonus stocksettle stock appreciation right policy director member corporate executive committee decision pension benefit term perfor take consideration personnel change mance share plan determine annually board director act recommendation remunera follow page provide detailed information remu tion committee remuneration committee continuously neration earn member board director track salary trend market world big phar member corporate executive committee maceutical company report board director information committee remit power proce dure make remuneration decision find remuneration bylaw roche board director remuneration member board director member board director receive follow revision remuneration policy include remuneration cash show table remuneration market comparison world major pharmaceutical member board director board activ company remuneration committee determine httpwwwrochecomaboutrochecorporategovernance list member position committee membership articleofincorporationhtm chairmanship remuneration member board director additional compensation remuneration committee memberschair additional special compensation chf chf humer remuneration chairman board director gehrig hoffmann baschera bell bulcke burns vink franz julius levinson oeri voser weder mauro remuneration member board director additional compensation remuneration committee memberschair additional special compensation chf chf frey ruttenstorfer exception member presidium vicechairmen board member receive chf year committee serve chf year committee chair high total remuneration member board director page remuneration serve vicechairman board prorate remuneration period march december prorate remuneration period january march roche business report remuneration reportitie remuneration member board director member board director receive remain unchanged remuneration totalling swiss franc swiss franc swiss franc cash payment nonexecutive member board director award share nonvoting additional remuneration pay members board equity security stocksettle stock appreciation right director ssar restrict stock unit rsus remuneration member corporate executive william burns receive honoraria amount total committee general provision assign authority dollar swiss franc serve mem decision corporate executive committee remuneration ber board director chugai pharmaceutical remuneration committee board directors ltd arthur levinson receive payment consult outline page remuneration report work board membership genentech amount dollar swiss francs john bell contractual obligation roche assign receive payment consult work scientific ment daniel oday receive swiss advisory board roche totalling swiss franc franc addition remuneration horst teltschik member board alan hippe receive additional payment cost occur director receive honoraria amount euros relocation switzerland etc amount swiss swiss franc serve board franc roche subsidiary germany stocksettle stock appreciation right ssar remuneration member board director remuneration member corporate executive committee base pay chf annual salary annual salary annual salary schwan ayyoubi hippe keller oday soriot total member corporate executive committee prorate remuneration period april december members corporate executive committee bonus receive remuneration totalling swiss franc member corporate executive committee receive million swiss franc million swiss bonus cash payment form franc roche nonvoting equity security block year block period accord corporate execu tive committee member individual decision cash payment end april roche nonvoting equity security grant beginning base remuneration member corporate executive committee include ahvivalv page market value average month remuneration report roche business report bonus bonus bonus bonus total total total chf chf chf schwan cash payment block nonvoting equity security total bonus ayyoubi cash payment block nonvoting equity security total bonus hippe cash payment block nonvoting equity security total bonus keller cash payment block nonvoting equity security total bonus oday cash payment block nonvoting equity security total bonus soriot cash payment block nonvoting equity security total bonus total member corporate executive committee calculation value consideration reduction value block period reduce market value year value grant date january chf nonvoting equity security number block nonvoting equity security grant base market value average month value chf nonvoting equity security calculation value consideration reduction value block period reduce market value year value grant date january chf nonvoting equity security number block nonvoting equity security grant base market value average month value chf nonvoting equity security include additional compensation successful integration genentech amounting chf pay prorate remuneration period april december number block nonvoting equity security grant schwan ayyoubi hippe keller oday soriot stocksettle stock appreciation right ssar ssar ssar ssar value chf value chf value chf schwan ayyoubi hippe keller oday soriot total member corporate executive committee stocksettle stock appreciation right ssar page blackschole value describe stocksettle stock appreciation right ssar page value accord annual report roche business report remuneration reportthe ssar grant strike provision plan number nonvoting price ne price december equity security reserve participant time value recipient change cycle number security actually award roche future ne price improves depend extent investment roche security share ne outperform average return member corporate executive committee additionally investment security issue peer set compara receive annual expense allowance swiss franc tor company comparison base security totalling swiss franc market price dividend yield total shareholder return tsr reduce effect shortterm market fluc performance share plan psp tuation security price average month member corporate executive committee october december prior start performance member senior management currently individu cycle month october december al worldwide participate performance share plan end cycle roche security perform psp well peer set addition roche tsr increase cycle board psp move overlap threeyear performance director elect increase maximum ne award cycle new cycle beginning year twofold event investment roche cycle progress psp psp security underperform average return deliver psp previous year psp peer company few ne award psp psp end december award target ne ne reserve plan member corporate executive committee show table board director decide actual level ne cash equivalent award cycle strike price table ssar footnote performance share plan psp total estimate value psp award award ne ne ne target award award award target number target number number ne ne psp ne psp psp psp psp psp value chf value chf value chf value chf schwan ayyoubi hippe keller oday soriot total member corporate executive committee total estimate value psp originally target ne award psp estimate value calculate yearend price december chf nonvoting equity security ne base number ne originally target subject change number value ne awardable plan december december respectively spread relevant period time year board director vote actual allocation ne originally target december december respectively accord tsr achieve remuneration report roche business report close financial year e industry accord term respectively aim psp provide incentive plan participant receive originally tar participant achieve steady value growth get ne table detail end psp cycle base indirect benefit month move average distribute dividend total employer contribution social security billion swiss franc billion swiss franc scheme pension plan groupwide employee stock billion swiss franc billion swiss purchase plan roche connect respect member franc tsr roche security nes share corporate executive committee show table indi rank compare peer set company operat rect benefit indirect benefit payment pension fundsmgb ahvivalv roche connect tax consulting service chf chf chf chf schwan ayyoubi hippe keller oday soriot total mgb stiftung der hoffmannla roche mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit ahvivalv swiss social security programme provide retirement disability unemployment benefit roche connect voluntary stock purchase plan offer member corporate executive committee maxi employee opportunity buy roche nonvoting equity mum notice period month connection security ne equal annual new company personnel structure member cor salary discount ne purchase plan porate executive committee receive compensation subject hold period year switzerland annual base pay case termination contract company termination fault base lack remuneration emolument loan performance age erich hunziker chief financial officer retire roche end march erich hunziker receive fol high total remuneration member lowing payment base exist contractual obligation board director salary swiss franc payment december franz humer chairman member board bonus swiss franc pay april high total remuneration remunera employer contribution pension fund etc swiss tion member board director page franc receive agree payment chairman remuneration consist base salary contract consist oneyear salary million swiss bonus award chairman board handover franc bonus million swiss franc payment executive function ceo annual general meeting include corporate executive committee mem march receive additional ssar ber total swiss franc ne new psp cycle long enrol roche ssar programme pension total swiss franc pay corporate executive committee member roche business report remuneration reporthigh total remuneration member board director chf chf chf salary bonus cash payment block nonvoting equity security total pension fundsmgb roche connect total value calculation value consideration reduction value year block period reduce market value year detailed calculation remuneration annual report mgb stiftung der hoffmannla roche mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit include additional compensation committee member chf payment tax consulting service chf chugai advisory mandate usd chf include employer contribution ahvivalv chf high total remuneration member corporate executive committee chf chf chf salary bonus cash payment block nonvoting equity security total ssar blackschole value grant minus pension fundsmgb roche connect estimate value target award ne accord performance share plan awardsvalue nes total total value calculation value consideration reduction value year block period reduce market value year detailed calculation remuneration annual report blackschole value describe stocksettle stock appreciation right ssar page mgb stiftung der hoffmannla roche mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit basic rule detailed calculation remuneration member corporate executive committee performance share plan footnote respectively include annual expense allowance chf payment tax consulting service chf exclude employer contribution ahvivalv payment high total remuneration member additional remuneration state pay corporate executive committee ment pay current member corporate severin schwan ceo member corporate executive committee executive committee high total remuneration remuneration member corporate execu tive committee page table remuneration report roche business report security holding director andr hoffmann andreas oeri member founder family closely associate belong shareholder group pool voting right end group hold share issue share detailed informa tion group find finance report note roche group consolidate financial statement relate party note financial statement roche holding ltd significant shareholder addition december member board director person closely associate member executive committee son closely associate held share ne show table stocksettle stock appreciation right ssar december franz humer william burns members board director hold ssar position member corporate executive committee hold stocksettle stock appreciation right ssar show table ssar ssar show table introduce roche january place stock option ssar entitle holder benefit financially increase value roche ne grant date exercise date strike price ssar term multi year plan closing price roche ne grant date ssar vest year grant date onethird vest end year onethird end year onethird end year vested ssar exercise convert ne seven year grant date unexercised ssar lapse compensa tion fair value ssar calculate date issue blackschole formula ssar tradable deduction average twoyear vest period strike price expiry date grant value ssar show table number ssar calculate time issue enter value table remuneration member corporate execu tive committee stocksettle stock appreciation right ssar roche business report remuneration reportsecurity holding december close relative share ne security holding number number numbertype number board director humer ssar rogtpk trackerplus cert zrcher kantonalbank roche genussschein rog underlie valor isin gehrig hoffmann ubs longshort certificate link roche bearer share roche nonvoting equity securities valor isin baschera bell bulcke burns ssar vink american depository receipts adr rhhby isin franz julius nes levinson oeri ubs longshort certificate link roche bearer share roche nonvoting equity securities valor isin voser weder mauro total nes corporate executive committee schwan nes ssar ayyoubi ssar hippe ssar keller share ssar oday ssar soriot ssar total ne share share hold shareholder group pool voting right list remuneration report roche business report ssar number ssar hold current member corporate executive committee december total corporate executive committee schwan ayyoubi hippe keller oday soriot total corporate executive committee member humer burn strike price chf market price ne december chf expiry date grant value ssar chf blackschole value minus franz humer receive additional ssar franz humer receive ssar member corporate executive committee william burns receive additional ssar william burn receive ssar member corporate executive committee roche business report remuneration reportindependent assurance report corporate governance sustainability committee criterion roche holding ltd basel roche roche group internal corporate responsibility report guideline base responsible care health safety perform assurance procedure provide assur environmental protection report guideline publish ance follow aspect corporate responsi european chemical industry council cefic sus bility report roche tainability report guideline publish global reporting initiative gri subject matter roche group internal corporate reporting manual ver datum information disclose corporate responsibility sion sustainability report economic performance report roche consolidate subsidiary exclud datum ing chugai pharmaceutical ltd business year define procedure people dona end december follow aspect tion sponsorship key figure gather collate indicate level assurance aggregate internally management reporting process respect good practice procedure internal reporting sys corporate responsibility report preparation tem process design manage operate people donation sponsorship key figure control environment relation datum aggre responsibility methodology gation key figure reasonable assurance accuracy completeness corporate responsibility key figure table page indicator subject inherent limitation give nature select people key figure disclose page method determine calculate estimate roche business report limited assur data assurance report read con ance nection roche internal guideline definition pro consolidated data information roche group cedure report corporate responsibility level relation donation sponsorship datum disclose formance exclude health care professional hcp relate activity limit assurance roche corporate governance sustainability commit tee responsible subject matter criterion responsibility provide conclusion subject matter base assurance procedure accordance international standard assurance engagement isae subject matter limited assurance evi dencegathering procedure limit rea sonable assurance example audit financial state ment assurance obtain overall reasonable assurance engagement roche business report independent assurance reportmain assurance procedure conclusion assurance procedure include follow work opinion evaluation application group guideline internal corporate responsibility report guideline review application roche internal corporate apply properly responsibility reporting donation sponsorship internal reporting system collect aggregate guide line people donation sponsorship key figure func site visit tione design provide appropriate basis visit select site roche pharmaceutical diag disclosure nostics division austria ukraine poland romania tur key ireland puerto rico selection base base work describe report assess quantitative qualitative criterion ment criterion come attention cause interview personnel responsible internal corporate believe corporate responsibility information man responsibility report datum collection site tione subject matter disclose corporate visit group level determine understand responsibility report roche business report ing application roche internal corporate responsibility fair picture roche performance guideline assessment key figure perform test sample basis evidence support zurich january select people donation sponsorship key fig ure roche accident rate energy consumption emis pricewaterhousecoopers sion relate energy consumption release halogenate hydrocarbon use water general waste headcountfte datum staff turnover labor practice information contri bution philanthropic organization patient organization health institution public policy body concern com clive bellingham stephan hirschi pleteness accuracy adequacy consistency review documentation analysis relevant policy basic principle review relevant documentation sample basis include group corporate responsibility policy manage ment report structure documentation assessment process data consolidation review appropriateness management reporting process corporate responsibility report assess consolidation process datum group level independent assurance report roche business report publish cautionary statement forwardlooke hoffmannla roche ltd statement basel switzerland annual report contain certain forwardlooking statement tel forwardlooke statement identify word believe expect anticipate project intend seek fax estimate future similar expression discussion thing strategy goal plan intention factor medium office cause actual result differ materially future group communication reflect forwardlooke statement contain annual basel switzerland report price product initiative competi tel tor legislative regulatory development economic con fax dition delay inability obtain regulatory approval bring ing product market fluctuation currency exchange rate general financial market condition uncertaintie dis investor relation covery development marketing new product new use basel switzerland exist product include limitation negative result clini tel cal trial research project unexpected effect pipeline fax market product increase government pricing pressure interruption production loss inability obtain adequate world wide web protection intellectual property right litigation loss key wwwrochecom executive employee adverse publicity news coverage corporate sustainability committee statement earning share growth profit tel forecast interpret mean roche earning email corporatesustainabilityrochecom earning share subsequent period nece sarily match exceed historical publish earning earning order publication share roche tel fax trademark mention enjoy legal protection email baselwebmasterrochecom link party page provide convenience express opinion content thirdparty page annual general meeting expressly disclaim liability thirdparty information march use roche annual report publish german english print nonchlorine bleach fsccertified paper roche annual report issue hoffmannla roche ltd basel group communications key figure highlight february march march roche group index study avastin show woman roche annual general meeting vote launch innovative fully auto sale mchf free cash flow mchf newly diagnose advanced ovar increase shareholder dividend mate clinical chemistry module ian cancer live significantly long cobas disease get bad research development mchf total dividend mchf operating profit mchf number employee april april roche announce positive clinical fda approve cobas hpv test investigational medicine metmab test result investigational medi cervical cancer screening combination tarceva double cine tdm aggressive form detect highrisk genotype time people lung cancer live metastatic breast cancer disease get bad income taxis mchf total employee remuneration mchf net income mchf patient clinical trial august september september marketing approval target roche name healthcare super tarceva receive european approval skin cancer medicine zelboraf sector leader dow jones firstline use genetically distinct core earning share chf ecoefficiency rate cobas braf test companion sustainability index type lung cancer diagnostic year run index index october november december price development nonvoting equity security genussschein chf investigational medicine ocrelizumab fda grant priority review new marketing application submit show significant reduction drug application vismodegib pertuzumab multiple sclerosis disease main advanced form skin cancer positive metastatic breast cancer taine year roche nonvoting equity security swiss market index rebase key figure index figure annual report core result index global reporting initiative gri propose board director indicator report development phase number exclude patient wwwrochecomreportingandindice genentech study initiate prior merger calculation ecoefficiency rate wwwrochecomenvironment rochearkey figuresengindd rochearhighlightsengindd hoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom roche annual report annual report landmark year roche personalise healthcare annual report highlight progress advance strategic priority share entire roche group successfully launch new test medicine tailor need specific patient popu lation good progress develop promise treatment safe effective roche believe medically differentiate product benefit healthcare stakeholder patient physician regulator payer rochearfront coverengindd rochearourbusinesstopicengindd